DK150690B - Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse - Google Patents
Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse Download PDFInfo
- Publication number
- DK150690B DK150690B DK639871AA DK639871A DK150690B DK 150690 B DK150690 B DK 150690B DK 639871A A DK639871A A DK 639871AA DK 639871 A DK639871 A DK 639871A DK 150690 B DK150690 B DK 150690B
- Authority
- DK
- Denmark
- Prior art keywords
- enzyme
- antibodies
- reaction
- specific binding
- hcg
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/971—Capture of complex after antigen-antibody reaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
- Y10S436/818—Human chorionic gonadotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
150690 ø
Det er kendt, at en komponent i reaktionen mellem et specifikt binderprotein og det tilsvarende bindelige stof kan bestemmes ved, at man inkuberer en af de omhandlede komponenter forsynet med en markør i en reaktionsblanding, som i det mindste indeholder den anden komponent, 5 og derpå iværksætter en adskillelse mellem den mærkede komponent, som henholdsvis er og ikke er bundet til dens bindingspartner og endelig bestemmer markøren i mindst en af de to fremkomne fraktioner. Fordelingen af den mærkede komponent over de to fraktioner er et mål for den mængde af den søgte komponent, som er til stede i prøven. Der 10 kan beskrives tre systemer, i hvilke den ovennævnte fremgangsmåde kan anvendes, a) antistoffer som specifikke binder-proteiner og de tilsvarende antigener som bindelige stoffer. Stoffer, som kan bestemmes 150690 . 2 på denne måde, er bl, a. proteinhormoner og deres antistoffer eller virus-antigener og deres antistoffer, b) antistoffer som specifikke binder-proteiner og haptener som bindeligt stof. Her defineres hap-tenerne som proteinfri stoffer, der kan reagere med antistoffer uden 5 at være i stand til at inducere dem. Stoffer, som kan bestemmes i et sådant system, er bl.a. steroidhormoner og vitaminer, c) proteiner, som i legemet virker som receptor- eller transport-molekyler som specifikke binder-proteiner og stoffer, som er bundet af dem som binde-lige stoffer. Dette system er f.eks. egnet til bestemmelse af ste-10 roidhormoner, men også af thyroxin og triiodthyronin, vitamin B12, den intrinsicole faktor og det adrenocorticotrope hormon.
De vigtigste punkter i de beskrevne analysemetoder er anvendelsen af en markør og adskillelsen af den mærkede komponent i en fraktion, 15 som er bundet, og en fraktion, som ikke er bundet til den tilsvarende komponent.
Fra beskrivelsen til dansk patentansøgning nr. 5462/71 kendes en fremgangsmåde, ved hvilken der anvendes enzymmærket komponent i forbindel-20 se med en kvantitativ immunologisk bestemmelse. Ved denne kendte fremgangsmåde sker adskillelsen mellem flydende og fast fase ved gelfiltrering, men denne metode er upraktisk og kan ikke give nogen pålidelig og let bestemmelse. Ved metoden kan immunokomponenter kun bestemmes i en koncentration på 50-100 nanogram pr. milliliter.
25
Fra beskrivelsen til dansk patentansøgning nr. 2812/67 kendes endvidere en fremgangsmåde, ved hvilken der gøres brug af uopløseliggjorte antistoffer overfor proteiner eller peptider, som er antigener, i en radio-immun bestemmelse. Radiaktive atomer anvendt som markører er 30 f.eks. 131j, 125^, 14^, 3^, 5?Co Denne fremgangsmåde er kendetegnet ved en høj følsomhed. Imidlertid er denne fremgangsmåde begrænset til institutter, hvor det nødvendige specielle apparatur er tilgængeligt.
Adskillelsesmetoderne kan opdeles på følgende måde: 35 a) Fremgangsmåder afhængige af forskellen i fysiske egenskaber mellem den ikke bundne, mærkede komponent og dens kompleks med bindings-partneren, såsom gel-filtrering, elektroforese, saltudfældning og absorption til dekstran-overtrukket trækul.
40 b. Den såkaldte fastfase-metode, ved hvilken den ene komponent allerede i forvejen er bragt i uopløselig form ved tværbinding eller ved 3 150690 covalent binding eller fysisk adsorption til en fast bærer, c) Den såkaldte dobbelte antistof«metode,ifølge hvilken det dannede kompleks, antigen (eller hapten)«antistof udfældes ved hjælp af antistoffer over for antistoffet i komplekset, hvilken fremgangsmåde 5 kun er kendt fra systemer, i hvilke antistoffer i opløst form kommer i betragtning«
Medens de under a) og c) omtalte fremgangsmåder er relativt komplicerede, lider de under b) omtalte af den ulempe, at en reaktions-10 komponent, når den bringes i uopløselig form, som regel vil mindske sin affinitet til reaktions-partneren. Imidlertid er en høj affinit« vigtig for tilvejebringelse af et følsomt prøvesystem.
Ifølge opfindelsen har man fundet en fremgangsmåde til bestemmelse 15 af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et koblingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det 20 specifikke binderprotein (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), hvilken fremgangsmåde er ejendommelig ved, at man yderligere anvender . uopløseliggjo.rte antistoffer oVér for det-< specif ikke binder-protein,·' og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller 25 faste fase af reaktionsblandingen. Denne fremgangsmåde muliggør bestemmelse af komponenter, der er til stede i en koncentration på 1-1C nanogram pr. milliliter.
I den foreliggende beskrivelse bruges begreberne conjugat og enzym-30 conjugat synonymt for koblingsproduktet af det bindelige stof og enzymet.
Det bindelige stof kan opdages og bestemmes ved, at man sammenbringer den ukendte prøve eller en fortyndingsserie af samme med en kendt 35 mængde af et conjugat af det stof, der skal bestemmes, og et enzym og med en mængde specifikt binderprotein i afhængighed af den mængde enzym-conjugat, som tilsættes. Derpå tilsættes en mængde, fortrinsvis et overskud af de antistoffer, der er gjort uopløselige over for det specifikke binder-protein, så at hele enzym-conjugatet, som har 40 reageret med binder-proteinet, ved hjælp af dette protein bliver koblet til disse uopløselige antistoffer. Jo mere bindeligt stof der ex 4 150690 til stede i prøven, jo mindre enzym-conjugat vil reagere med det specifikke binder-protein og sluttelig komme i den uopløselige fase. Resultatet bliver, at mere ubundet enzym-conjugat forbliver i den flydende fase og på simpel måde kan bestemmes der. Det specifikke 5 binder-protein kan bestemmes ved, at man inkuberer prøven eller fortyndingsserier af denne med en kendt mængde enzym-conjugat og med en mængde af de over for det specifikke binder-protein uopløselig-gjorte antistoffer. Enzymaktiviteten kan kun finde sted i den uopløselige fase, hvis conjugatet har reageret med det specifikke bin-10 der-protein, d.v.s. jo mere specifikt binder-protein, der er i prøven, jo mindre bundet enzym-conjugat vil forblive i den flydende fase.
Den beskrevne analyse-metodes følsomhed kan varieres ved at ændre mængderne af reagenserne. Imidlertid er den mængde enzym-conjugat, 15 som kan anvendes, begrænset nedefter af kravet om, at dets enzymaktivitet kan måles på rimelig måde, hvorfor analyse-metodens følsomhed har sin begrænsning. Den minimalt målelige enzym-aktivitet er bl. a. afhængig af naturen af det enzym, der anvendes ved koblingen, og af substratets natur og endelig af enzym-reaktionens 20 inkubationstid. Fremdeles indvirker det specifikke binder-proteins affinitet stærkt på bestemmelsens følsomhed. Ved en analyse-metode af høj følsomhed kræves specifikke binder-proteiner med en høj affinitet.
25 Mængderne af de for en bestemmelse nødvendige reagenser må fastlægges ad empirisk vej.
Til bestemmelsen af det bindelige stof må mængden af enzym-conjugatet bestemmes ved hjælp af enzymaktiviteten. Derpå inkuberes denne mængde 30 med en fortyndingsserie af det specifikke binder-protein til bestemmelse af den nødvendige mængde af dette protein. Fortrinsvis vælger man en mængde specifikt binderprotein, som kan binde 50-90% af enzym-conjugatet. Til sidst undersøger man, hvorvidt den ønskede følsomhed så er blevet nået, idet man undersøger en fortyndingsserie af 35 det stof, der skal undersøges ved metoden.
Til bestemmelsen af det specifikke binder-protein må der angående doseringen af enzym-conjugatet tages hensyn til dettes aktivitet, som skal kunne bestemmes med rimelig nøjagtighed.
s 150690
De antistoffer over for det specifikke binder-protein, der er gjort uopløselige, tilsættes fortrinsvis i overskud ved de to bestemmelses-måder. Disses dosering bestemmes ved forudgående forsøg.
5 Denne fremgangsmådes fordele over for de kendte er, at kombinationen af "Dobbelt Antistof" og "Fast Fase"-metoden, i det følgende af bekvemmelighedsgrunde betegnet DASP-metoden, frembyder adskillige fordele over for de kendte fremgangsmåder. Således er udførelsen af den nye fremgangsmåde, d.v.s. tilførsel af uopløseliggjorte anti-10 stoffer over for det specifikke binder-protein, inkubation, centrifugering og måling, meget simpel, doseringen er ofte lettere end ved fast-fase-metoderne, fordi det er tilstrækkeligt at tilsætte et overskud af uopløst materiale, hvorimod man ved fast-fase-metoderne skal bruge en nøjagtigt udmålt mængde af det faste materiale. Frem-15 deles er affiniteten hos binder-proteinet til det bindelige stof ikke svækket af bindingen til bærermaterialet, således som det kan være tilfældet ved fast-fase-metoden. En yderligere fordel over for den sidste fremgangsmåde er den hurtige ligevægt-indstilling hos reaktionen mellem det specifikke binder-protein og det bindelige stof 20 (begge i opløsning). En yderligere fordel består i, at ved DASP- fremgangsmåden kan det uopløseliggjorte antistof, nedenfor betegnet immunoadsorbenten, bruges i ethvert system, i hvilket man bruger antistoffer som specifikke binder-proteiner, forudsat at disse antistoffer er præpareret i de samme dyrearter. På den anden side, for 25 ethvert antigen eller hapten, der skal bestemmes efter fast-fase-metoden, skal antistofferne gøres uopløselige. Den dobbelte antistofmetode er meget følsom over for relativt små ændringer i saltkoncentrationerne, pH og lignende, som gør en vidtgående kontrol af betingelserne nødvendig. Yderligere kræver metoden tilføjelse af 30 "bærer"-γ-globulin og følgelig meget andet antistof til opnåelse af et immunt precipitat. Foruden at være en mere enkel fremgangsmåde fører DASP-metoden, som ikke kræver "bærer"-γ-globulin, til besparelse af materialer. Endelig skal det nævnes, at en dobbelt antistoflignende adskillelse anvendt ved transport- eller receptor-proteiner 35 ikke er mulig, da der ikke kan fremskaffes et "bærer"-protein til dette formål. Fremgangsmåden ifølge opfindelsen frembyder derfor en enestående lejlighed i denne henseende.
Fremgangsmåden ifølge opfindelsen kan let gøres automatisk. Det er 40 principielt muligt at bringe reaktionskomponenterne sammen straks _ t t _ . i _ j . _ -? , » t_ _ i i ^ ^___ ^ r Λ__i · T __ __ i i____ 6 150690 man dog fortrinsvis de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens, idet det har vist sig, at bestemmelsen derved får en højere følsomhed.
5
Ved fremgangsmådens anvendelse til bestemmelse af det bindelige stof går man af samme grund hensigtsmæssigt frem på den måde, at man først til prøven sætter det specifikke binder-protein og derpå enzym-con-jugatet og til sidst de uopløselige antistoffer over for det speci-fikke binder-protein.
Det for opfindelsen nødvendige reagens, d.v.s. koblingsproduktet af antigen, hapten eller det bindelige stof med enzymet, kan fremstilles på kendt måde. Disse fremgangsmåder kan også bruges til at bin-15 de et hapten eller et lavmolekulært bindeligt stof til et enzym, forudsat at et af stofferne har en eller flere aminogrupper og det andet en eller flere carboxylgrupper. Hvis det sidste ikke er tilfældet, er det muligt at indføre den ønskede gruppe i molekylet, som skal kobles, ved hjælp af en kendt organokemisk proces. Der kendes 20 også fremgangsmåder til sammenbinding af amino- og carboxylgrupper, eventuelt ved at indføre en bro. Endelig kan komponenter som glutar-aldehyd, difluordinitrodiphenylsulfon og di- og tri-chloro-s-tria= zin ofte anvendes til den omhandlede kobling. Det kan blive nødvendigt at adskille de fremstillede enzymconjugater fra uomdannede stof-25 fer og fra stoffer, som er blevet inaktive. Til dette formål kan man benytte kendte fremgangsmåder, såsom udfældning med organiske opløsningsmidler, gelfiltration og centrifugering ved en vægtfyldegradient .
20 Valget af det enzym, der benyttes i koblingsproduktet, er bestemt ved et antal egenskaber hos enzymet. Naturligvis er det vigtigt, at enzymet er resistent over for koblingen med et andet molekyle, d.v.s. over for ændring af en eller flere aminosyre-sidekæder. Enzymets specifikke aktivitet er også af stor vigtighed. Da en mindre mæng-25 de enzym—conjugat behøver at tilføjes for at opnå en målelig enzympåvirkning, bliver undersøgelsessystemet mere følsomt. Fremdeles bør man foretrække de enzymer, hos hvilke en bestemmelse af aktiviteten kan foretages på en simpel måde, I første række bør man tage de enzymer i betragtning, for hvilke aktiviteten kan béstemmes kolorime-40. trisk, épektrofotometrisk eller fluorimetrisk. Sådanne bestemmelser 7 150690
Man kan bestemme aktiviteten af de, .enzymer kolorimetrisk, som katalyserer en reaktion, ved hvilken der. .opstår eller forsvinder et farvet stof, enten ved den primære eller den sekundære reaktion.
5 Som enzymer, der- kan" anvendes som den enzymatisk; aktive komponent i conjugater, skal nævnes catalase, peroxidase (3-glucoronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose-oxidase, galactose-oxidase og alkalisk phosphatase.
10 Ved afslutningen af reaktionen mellem komponenterne og reagenserne kc man ifølge opfindelsen bestemme enzymaktiviteten i den flydende ellei den faste fase, eller i begge faserne af reaktionsblandingen. Det simpleste er imidlertid at bestemme enzymaktiviteten i den flydende fase, 15
De antistoffer, der er gjort uopløselige over for de specifikke binde proteiner, som også er vigtige reagenser for fremgangsmåden ifølge op findelsen, kan også fremstilles på kendt måde. Antistofferne kan fremstilles, idet man tager et renset præparat af det specifikke bin-20 der-protein eller af de proteiner, som har i det mindste delvis de sa me antigen-egenskaber som det specifikke binder-protein, og så injice rer dette på kendt måde i en anden dyreart end den, fra hvilken man fik det. Det behandlede dyrs serum eller gamma-globulin-fraktionen af dette kan gøres uopløseligt ved kryds-led-forbindelse med sådanne sto 25 fer som glutaraldehyd og chlormyresyre-ethylester eller ved binding t faste bærerpartikler enten fysisk eller adsorptivt eller kemisk ved dannelse af covalente bindinger. Som faste bærere kan anvendes sådanm stoffer som cellulose (ændret eller ikke), agarose, kryds-led-forbundi dekstran, polystyren og lignende. En covalent binding til disse stof· 30 fer af antistoffer kan foretages ved hjælp af sådanne stoffer som car: bodiimider, di- og tri-chloro-s-triaziner, glutaraldehyd, cyanogenbro-mid og f.eks. ved diazotering.
Fordelene ved fremgangsmåden ifølge opfindelsen til bestemmelse af 35 binderprotein opnås, hvis man anvender et overskud af uopløselige ant: stoffer, således at det specifikke binderprotein går helt over i den faste fase.
De former, i hvilke reagenserne kan anvendes, er mangfoldige. Den 40 enzym-conjugerede komponent i reaktionssysternet kan frysetørres eller 8 150690 opløses i en stødpude. Man kan også bruge en fast bærer, f,eks. en papirstrimmel imprægneret med conjugatet. Denne anvendes også til de nødvendige binder-proteiner.
Den uopløselige komponent kan bringes i form af partikler af forskellig størrelse, såsom granuler, flager, stave eller i form af en strimmel af et eller andet bæremateriale.
Opfindelsen angår endvidere en analysepakke til bestemmelse af * et specifikt binder-protein eller det tilsvarende bindelige stof ved den beskrevne fremgangsmåde, hvilken analysepakke er ejendommelig ved at den hovedsagelig indeholder: a) en kendt mængde conjugat af det bindelige stof og et enzym, ’ b) en kendt mængde binder-protein, hvis analysepakken skal anvendes til bestemmelse af det bindelige stof, c) én kendt mængde uopløseliggjorte antistoffer rettede imod det binderprotein, som er tilsat, eller som skal bestemmes, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
i
Analysepakken kan fremdeles indeholde de nødvendige yderligere midler til analysens udførelse, såsom reagensglas, pipetter og flasker med opløsninger.
Analysepakken kan særlig hyppigt og med særlig fordel anvendes til opdagelse og bestemmelse af et antigen eller et hapten, og til dette formål indeholder den i hovedsagen: a) en kendt mængde af et conjugat af antigenet eller haptenet og et enzym, b) en tilsvarende mængde af tilsvarende antistoffer, c) en kendt mængde uopløseliggjorte antistoffer, rettede imod de anvendte antistoffer, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
Når man anvender sådanne analysepakker til påvisning og bestemmelse af antistoffer, behøver man ikke de under b) nævnte antistoffer.
150690 9
En vigtig udførelsesform for en analysepakke ifølge opfindelsen er én ana-lysepakke til bestemmelse af de gonadotrope hormoner og særlig til bestem' melse af HCG (Human Chorionic Gonadotropin) som et middel til bestemmelse 5 af graviditet allerede på et meget tidligt stadium, hvilken analysepakke er ejendommelig ved, at den består af en beholder, der som væsentlige bestanddele i lyofiliserede lag indeholder: a) en bestemt mængde af et HCG-conjugat og et enzym, f.eks. HCG-peroxidase b) en bestemt mængde anti-HCG, c) en bestemt mængde uopløseliggjorte antistoffer oyer for anti-HCG sammei med et substrat til bestemmelse af enzymaktiviteten af det resterende HCG-enzym i den flydende fase.
Ved tilsætning af en vis mængde urin fra en formodet gravid kvinde, til 15 denne analyseblanding og ved at inkubere urinen med disse bestanddele dannes der en blanding af uopløseligt stof, idet den øvrige del indeholder det tilbageblevne opløselige HCG-enzym-conjugat. Mængden af det sidste afhænger af mængden af HCG i den undersøgte urin. Ved bestemmelse af enzymaktiviteten hos dette tilbageblevne HCG-enzym-conjugat kan man 20 fastslå, om urinen skyldes en gravid kvinde eller ej.
En fremgangsmåde, der fortrinsvis anvendes ved bestemmelsen af enzymaktiviteten, består i, at man bringer et indikator-papir imprægneret med enzymreagenser, f.eks, hvis der bruges en peroxidase, en H„09-forsyner så- 25 ^ ^ som urinstof-EL^,med et farvereagens såsom o-tolidin.
Ved korrekt valg af mængderne af hvert af reagenserne bliver det muligt at fastslå graviditet allerede på et meget tidligt stadium og på en simpel, hurtig og meget pålidelig måde, som kan udføres af en ikke opøvet 30 person.
150690 10
Eksempel 1.
Bestemmelse af det menneskelige chloriongonadotropin (HCG).
5 a) Fremstilling af HCG-HRP.
5 mg HCG og 20 mg peberrods-peroxidase (HRP) opløses i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Efter tilsætning af ko μΐ 25$ glutaraldehyd-ορløsning rystedes “blandingen i 2 timer ved stuetemperatur. Efter 5 minutters centrifugering ved 250 g fraktioneredes væsken over Sephadex G-200 i 0,05 M phosphat= stødpude med pH-værdien 6,2. Fraktionerne, hos hvilke den højeste enzymaktivitets $ var bundet af antistoffer overfor HCG brugtes under analysen.
15 b) Fremstilling af antistoffer overfor HCG.
Antistoffer overfor HCG indiceredes i kaniner som angivet af Schuurs et al. Acta Endocr. (Kbh) 59j 120,(1968).
c) Fremstilling af antistoffer overfor kanin-y-globulin.
2q Kanin-Y-globulin isoleredes fra normalt kanin-serum ved udfældning med l8$ w/v fast natriumsulfat. Antistoffer overfor dette fremstilledes ved immunisering af et får i overensstemmelse med følgende skemai 25 dag mængde Freud's adjuvans injektionsmåde 0 o,5 mg + intramuscular 1^· o,5 mg + intramuscular 28 1 mg + intramuscular b2 1 mg - intravenøs 3Q 56 1 mg - intravenøs den 70.dag blev fåret åreladt.
d) Fremstilling af immunoadsorbent-eellulose /får-anti-(kanin-γ-globu= 35 lin)7.
γ-globulinfraktionen af fåre-serumet beskrevet under c) fremstilledes ved udfældning med 165¾ w/v fast natriumsulfat. Efter vaskning optoges udfældningen i så meget 0,05 M borat-stødpude med pH-værdien 8,6, at den fremkomne proteinkoncentration udgjorte 10 mg/ml.
4Q 350 mg m-aminobenzyloxymethylcellulose opslemmedes i 50 ml destilleret 11 15069¾ vand og diazoteredes ved tilsætning af 10 ml 30$ saltsyre og dråbevis tilsætning af 10 ml 10$ NaDiK^-opløsning ved 0°C. Op-slemningen centrifugeres. Den vaskedes, og bundfaldet resuspendere-des i *+3 ml 0,05 M natriumborat med pH-værdien 8,6, derpå tilsattes 5 7 ml af den fremstillede γ-globin-opløsning. Blandingen omrørtes i 26 timer ved å-°C, hvorpå den centrifugeredes og vaskedes med 0,02 M phosphat-stødpude med pH-værdien 6,0.
e) Bestemmelse af HCG
10 Der fremstilledes en fortyndingsserie (32 -16-8-^-2-1-o,5-IU/ml) af HCG i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ v/v normalt fåreserum.
0,5 ml af hver af de HCG-indeholdende prøver inkuberedes med 0,1 ml kanin-(anti-HCG)-serum og 0,1 ml HCG-KRP-conjugat, begge i passen-15 de fortynding i eii halv time’ved stuetemperatur. Derpå tilsatte 0,3 ml af immunoadsorbenten (10 mg/ml) fremstillet ifølge d),og den fremkomne blanding omrørtes i en time ved stuetemperatur. Efter centrifugering bestemtes enzymaktiviteten: resten ved at blande 0,5 ml .
af denne væske med 1,5 ml substrat (10μ1 30$ ^.$2 °& 20 mg 5-amino--20 salicylsyre i 150 ml 0,02 M phosphatstødpude med pH-værdien.6,0), og efter 30 minutter ved 25°C måltes ekstinctionen ved 1+60 mm.
På denne måde påvistes det, at det var muligt at opdage en HCG-koncentration fra 0,5 til lIU/ml i prøven. Ved denne metode kunne man også undersøge urinprøver. Undersøgelsen er derfor egnet til 25 en graviditetsprøve. Forholdet til en eksisterende undersøgelsesmetode, en hæmaglutinations-·inhibitions-prøve var god. Det påvistes muligt at forøge systemets følsomhed ved anvendelse af en pre-incubation. Her incubereres prøven først med antiserumet og derpå tilsattes HCG-HRP-conjugatet.
30
Eksempel II.
Bestemmelse af insulin og anti-insulin.
a) fremstilling af insulin-(glucose-oxidase).
35 Der opløstes 5 mg grise-insulin af 25 mg glucose-oxidase i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,5. Hertil sættes 5 μΐ glutaraldehyd-opløsning, hvorefter blandingen rystedes i 90 minutter ved stuetemperatur. Blandingen fraktionereres over Sephadex 150690 12 G-200 i 0,05 M phosphat-stødpude med pH-værdien 6,5.De .fraktioner, af hvilke den højeste procentiske enzym-aktivitet kunne hindes af antistoffer overfor insulin, anvendtes ved analysen 5 b) Fremstilling af antistoffer overfor insulin.
Man ggv·' 10 marsvin &n;- ugentlig intramuskulær injektion med 1 mg grise-insulin i fuldstændig Freud's adjuvans gennem en periode på ^+-8 uger. Efter 10 ugers hvile gav man dyrene yderligere 1 mg insulin ved intravenøs injektion uden adjuvans. To uger senere blev 10 dyrene åreladt. Man modarbejdede den tilstødende hypoglycæmi ved intraperional administration af glucose.
c) Fremstilling af antistoffer ' overfor. maxsvin-γ-globulin.
Der . fremstilledes marsvin-Y-globulin ved tilsætning af 1 15 volumen ^mættet ammoniumsulfat-opløsninq til 2 volumen marsvine- serum. Den fremkomne udskillelse vaskedes to gange med 33i° mættet ammoniumsulfat-opløsning, hvorefter den optoges i en fysiologisk saltopløsning. Derpå immuniseredes et får med voksende doser af det fremstillede γ-globulin: 0,5 - 1 og 2 mg. Injektionerne blev 20 givet hver anden uge, idet immunogenet var blandet med fuldstændig
Freud's adjuvans. To uger efter den sidste injektion gaves der yderligere 2 mg γ-globulin i en fysiologisk saltopløsning, og en uge senere blev dyret åreladt.
25 d) Fremstilling af uopløselige antistoffer overfor marsvin-Y-globulin.
10 g mikrokrystallinsk cellulose aktiveredes ved, at det under omrøring sattes til H00 ml 2,5$ w/v CWBr-opløsning, hvorefter pH-værdien øgedes til 10,5 nied 1 N NaOH-opløsning, idet denne værdi opret 30 holdtes i 2 minutter. Derpå vaskedes cellulosen med isvand og med 0,1 M NaHCOy Der tilsattes 1,6 g Na^SO^ til 10 ml fåre-anti( marsvin.-γ-globulin) -serum. Efter en times omrøring ved stuetemperatur centrifugeres udfældningen. Der vaskedes to gange med 20 ml 16$ w/v Na^O^-opløsning, hvorefter det optoges i 10 ml 0,1 M NaHCO^-35 opløsning. Den aktiverede cellulose blandedes med *+0 ml 0,1 M NåKCO^- opløsning og de 10 ml γ-globulin-opløsning. Denne suspension om-rørtes i ^0 timer ved ^°0 og vaskedes efterhånden to gange med 150690 13 500 ml 0,5 M NaHCO^j to gange med 500 ml 0,05 M citrat af pH-værdien 1,1 og to gange med 500 ml 0,05 M phosphat af pH-værdien 6?5 5 e) Bestemmelse af antistoffer overfor insulin.
0,1 ml insulin-(glucose-oxidase) inkuberedes i passende fortynding med 0,*+ ml af en fortynding s serie af en marsvin-anti-insulin-serum i timer. Fortynding s s er i en foretoges med 0,05 M phosphat-stødpude med pH-værdien 6,0. Derpå tilsattes 0,3 ml immunoadsorbent 10 (15 mg/ml) og 0,2 ml stødpude, og blandingen omrørtes natten over ved *f°C. Efter centrifugering bestemtes enzymaktiviteten'af den resterende opløsning ved incubering af 0,5 ml af denne med 2,5 ml substrat i 30 minutter, hvorpå man målte ekstinetionen ved *+60 nm. Substratet indeholdt 50 mg glucose, 10 μg peroxidase og 1 mg 15 5- amino salicyl syre pr. 2,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,0.
Med dette system kunne antistofindholdet i de forskellige slags serum sammenlignes. Som referencepunkt valgtes den serumfortynding, hvor 5o5 af den totale kombinerbare enzymaktivitet er bundet.
20 f) Bestemmelse af insulin.
0,2 ml af en fortyndingsserie af insulin incuberedes i 2 timer med 0,1+ ml anti-insulin-serum i en sådan fortynding, at den kunne binde 60$ af det tilsatte enzym-conjugat. Derpå tilsattes 0,1 ml 25 insulin-(glucose-oxidase) · des i timer. Endelig tilsattes 0,3 ml immunoadsorbent (15 mg/ml). Blandingen omrørtes natten over ved H°C. Efter centrifugering måltes enzymaktiviteten i resto. løsningen som angivet under e). Bestemmelsens følsomhed, som afhænger af det anvendte antiserum, lig-30 ger indenfor nanogram-ordenen: 20-100 mg/ml, d.v.s* 0,5-2,5 mU/ml.
Eksempel III.
Bestemmelse af oestradiol.
35 a) Fremstilling af oestradiol-17-succinyl-HRP.
50 mg oestradiol-17-hemisuceinat og 0,08 ml tri-n-butylamin opløstes i 2,5 ml dioxan. Til den kolde (2°C) opløsning sattes 15 Hl isobutylchlorocarbonat. Efter 3o minutter blandedes denne opløsning
lif T5069Q
med 100 mg peberrodsperoxidase (HRP) i 7?5 ml af en dioxan/vand-blanding (2:3)5 som var indstillet til en pH-værdi på 9j5 med natriumhydroxid. Opløsningen omrørtes i *+ timer ved 2°C og dialyseredes derpå i 18 timer. Udfældningen, der var dannet efter at dialysatets 5 pH-værdi var indstillet til *+,6, centrifugeredes fra, vaskedes og op toges i 5 ml destilleret vand, som var indstillet til en pH-værdi på 8. Stoffet rensedes yderligere ved to ganges udfældning med 10 ml acetone. Det færdige produkt optoges i 10 ml 0,05 M piiospliat-stødpude med pH-værdien 738.
10 b) Fremstilling af østradiol-17-suecinyl-BSA.
Fremstillingen foretoges ifølge den blandede anhydrid-metode, som er angivet i eksempel Illa. Denne fremstilling foretoges, idet man gik ud fra 100 mg østradiol-17-hemisuccinat og 150 mg hornkvægsse-15 rum-albumin (BSA).
c) Fremstilling af antistoffer overfor østradiol.
Man injicerede et får en gang i *+ uger med k mg østradiol-17-succinyl-BSA i fuldstændig Freund's adjuvans. Med regelmæssige mellem 20 rum udtoges der blod fra dyret. Serumet absorberedes med BSA, som var gjort uopløseligt.
d) Fremstilling af antistoffer overfor fåre-Y-globulin.
Der fremstilledes fåre-Y-globulin som angivet i eksempel I, men nu 25 med 16$ w/v natriumsulfat. Man immunicerede så kaniner med denne fåre-Y-globulin efter følgende skema:
Dag mængde Freund's ad.iuvans innektionsmåde 0 200 ^g + intramuskulær 30 lb *+00 μg + ' " 28 800 μg + " b2 800 ug - intravenøs o c 2 Uger efter den sidste injektion blev dyret åreladt.
i5 150690 e) Fremstilling af immunoadsorbenten /kanin-anti (-fåre-Y-globulin)_7-cellulose.
Y-Globulinfraktionen fra de antisera, der er angivet under d), fremstilledes ved udfældning med 18$ w/v Wa^SO^. Det fremkomne produkt 5 kobledes med cellulose efter Gurvich's metode, angivet i eksempel I.
f) Bestemmelse af østradiol.
Immunreaktionen udførtes i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ BSA.
10 5 ml af prøven blandedes med 0,1 ml af fåre-anti-østradiolserumet i den ønskede fortynding. Efter 30 minutters inkubation ved stuetemperatur tilsattes 0,1 ml østradiol-17-succinyl-HRP i en passende fortynding, hvorefter der fulgte en anden 30 minutters inkubation 15 ved stuetemperatur. Derpå tilsattes Qf3 ml immunoadsorbent"su" spension (30 mg/mll, og blandingen omrørtes i 2 timer ved stue" temperatur. Derpå adskiltes den flydende og den faste fase ved centrifugering. Enzymaktiviteten i den flydende bestanddel måltes som angivet i eksempel I. Man kunne anvende fåre-anti-østradiol-20 serumet i fortyndinger fra 1:1600 til 1:12800 i afhængighed af kva liteten af det anvendte østradiol-17-succinyl-HRP. Ved en fortynding af 1:12800 af antiserumet kunne en østradiol-koncentration på 10 ng/ml opdages i prøven. Østradiol og østron viste en krydsreaktion i dette system.
25
Eksempel IV
Bestemmelse af cortisol og corticoid-bindende globulin.
a) Fremstilling af cortisol-21-(galaktose-oxidase).
30 Man koblede 50 mg cortisol-21-hemisuccinat og 100 mg galaktose- oxidase ved hjælp af den blandede anhydrid-teknik angivet i eksempel Illa.
b) Corticoid-bindende globulin (CBG) isoleredes fra human serum ved 35 hjælp af successions-kromatografi over DEAE-cellulose og hydroxyl- apatit.
Antistoffer overfor dette fremstilledes ved injicering af kaniner i 1^—dagesmellemrum med 500 Pg CBG i fuldstændig Freund's adjuvans.
Efter 3 måneder injiceredes dyrene med 1 mg CBG, og 2 uger senere i6 150690 c) γ-Globulin- fraktionen af anti-CBG- serum koblede s til m- aminobenzy1= oxymethylcellulose som angivet i eksempel III.
d) Bestemmelse af cortisol.
5 0,5 nil af en prøve, der indeholdt cortisol (standard-opløsning) ekstraheredes med 2 x 3 nil methylenchlorid. Den sammenbragte ekstraktionsvæske inddampedes til tørhed. Residuenten optoges i 0,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Derpå blandedes med 0,1 ml af en opløsning af CBG i den samme stødpude i en passende 10 koncentration, og der inkuberedes i 30 minutter ved h°C. Derpå tilsattes 0,1 ml cortisol-21-(galaktose-oxidase), også i passende fortyndingjOg 0,3 ml af immunoadsorbenten, der fremstilledes under c), med en koncentration af 5 mg/ml. Den fremkomne blanding omrør-tes i 2 timer ved ^°0 og derpå centrifugeredes, hvorefter enzymakti-15 viteten måltes i restvæsken. I den anledning tilsattes 0,5 nil af samme til 1,5 ml substrat bestående af 100 mg D-galaktose, 20 mg 5-aminosalicylsyre og 10 Mg peroxidase i 150 ml 0,02 M phosphat-stødpude med pH-værdien 6,0. Efter 30 minutter måltes ekstinctionen ved *+60 nm. Ved anvendelse af en CBG-koncentration på O,1* Mg/ml og 20 'så meget cortisol-21-(galaktose-oxidase), at 80$ af enzym-konjugatet var bundet til immunoadsorbenten, uden at der tilføjedes steroider, viste det sig muligt at bestemme mængder af fra 3 til 30 ng cortisol e) Bestemmelse af CBG var også mulig med de angivne reagenser. Fra en 25 fortyndingsserie af transcortin, rækkende fra O til 1280 ng/ml in kuberedes 0,5 ml i 15 minutter med 0,2 ml cortisol-21-(galaktose-oxidase) i passende fortynding. Derpå tilsattes 0,3 ml immunoad-sorbent-suspension (5 mg/ml), og blandingen omrørtes i 15 minutter. De to inkubationer holdtes ved Η-°ϋ. Derpå måltes enzymaktiviteten 30 i restvæsken som under d) c Analysemetodens følsomhed viste sig at være 50 ng/ml).
Eksempel V
35 I en flaske lyofiliseredes efterhånden følgende reagenser i adskilte lag: 0,3 ml af immunoadsorbent-suspensionen (10 mg/ml) som angivet i eksempel la.
40 2) 0,1 ml af en Ifo mannitol-opløsning.
Claims (2)
1. Fremgangsmåde til bestemmelse af en komponent i reaktionen 2Q mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et kob'lingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det specifikke binderyprotein 25 (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), kendetegnet ved, at man yderligere anvender uopløseliggiorte antistoffer over for det specifikke binder-protein, og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller den faste fase af 3Q reaktionsblandingen. 1
2 Fremgangsmåde ifølge krav 1, kendetegnet ved, at man tilsætter de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens. 35 2 Fremgangsmåde ifølge krav 2 til bestemmelse af det bindelige stof, kendetegnet ved, at man først til prøven sætter det specifikke binder-protein og derpå enzymconjugatet og til sidst de uopløselige antistoffer over for det specifikke binder-
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7018838 | 1970-12-28 | ||
| NL707018838A NL154599B (nl) | 1970-12-28 | 1970-12-28 | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK150690B true DK150690B (da) | 1987-05-25 |
| DK150690C DK150690C (da) | 1988-06-06 |
Family
ID=19811894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK639871A DK150690C (da) | 1970-12-28 | 1971-12-28 | Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof ved enzym-immunoanalyse |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US3839153A (da) |
| JP (3) | JPS5834783B1 (da) |
| AT (1) | AT320145B (da) |
| AU (1) | AU467394B2 (da) |
| BE (1) | BE777309A (da) |
| BR (1) | BR7108553D0 (da) |
| CA (1) | CA964560A (da) |
| CH (1) | CH557030A (da) |
| DE (1) | DE2164768B2 (da) |
| DK (1) | DK150690C (da) |
| EG (1) | EG11604A (da) |
| ES (1) | ES398372A1 (da) |
| FI (1) | FI54034C (da) |
| FR (1) | FR2120835A5 (da) |
| GB (1) | GB1348938A (da) |
| IL (1) | IL38371A (da) |
| IT (1) | IT965020B (da) |
| NL (1) | NL154599B (da) |
| SE (1) | SE398557B (da) |
| ZA (1) | ZA718332B (da) |
Families Citing this family (882)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE31006E (en) * | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
| NL171930C (nl) * | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3790447A (en) * | 1972-07-05 | 1974-02-05 | Abbott Lab | Streptococci diagnostic method |
| DE2333434C3 (de) * | 1973-06-30 | 1978-04-06 | Istvan D. Dr. 5024 Pulheim Bartos | Verfahren zur Durchführung serologischer Untersuchungen nach dem Prinzip der Komplementbindungsreaktion und gebrauchsfertige Schnelltestpackung hierfür |
| US4239746A (en) * | 1973-06-30 | 1980-12-16 | Dezso Istvan Bartos | Complement fixation test employing reactants in a disposable package |
| US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| GB1508132A (en) * | 1974-05-20 | 1978-04-19 | Technicon Instr | Analysis of biological fluids |
| US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
| US4001087A (en) * | 1974-10-10 | 1977-01-04 | The United States Of America | Affinity labelling enzymes with esters of aromatic sulfonic acids |
| FR2288312A1 (fr) * | 1974-10-14 | 1976-05-14 | Pasteur Institut | Procede de dosage immunoenzymatique de la progesterone |
| US4002532A (en) * | 1974-10-21 | 1977-01-11 | Weltman Joel K | Enzyme conjugates |
| SE388694B (sv) * | 1975-01-27 | 1976-10-11 | Kabi Ab | Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar |
| NL7501215A (nl) * | 1975-02-01 | 1976-08-03 | Akzo Nv | Methode voor het aantonen en bepalen van een antigeen of antilichaam. |
| US4629688A (en) * | 1975-04-28 | 1986-12-16 | Miles Laboratories, Inc. | Homogeneous specific binding assay method |
| US4230797A (en) * | 1975-04-28 | 1980-10-28 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a coenzyme as label |
| USRE32696E (en) * | 1975-09-04 | 1988-06-14 | Akzona Incorporated | Enzymatic immunological method for determination of antigens and antibodies |
| US4474878A (en) * | 1975-09-29 | 1984-10-02 | Cordis Laboratories, Inc. | Sandwich EIA for antigen associated with hepatitis |
| SE7610683L (sv) * | 1975-09-29 | 1977-06-10 | Cordis Corp | Metod for bestemning av nervaron av ett antigen associerat med hepatit |
| US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
| JPS5272284A (en) * | 1975-12-12 | 1977-06-16 | Dainippon Pharmaceutical Co | Enzymeeimmunoassay reagent |
| US4045384A (en) * | 1976-07-23 | 1977-08-30 | The Dow Chemical Company | Method for forming an amide bond between a latex and protein |
| GB1549069A (en) * | 1976-12-10 | 1979-08-01 | Erba Farmitalia | Enzyme linked immunoassay |
| US4407943A (en) * | 1976-12-16 | 1983-10-04 | Millipore Corporation | Immobilized antibody or antigen for immunoassay |
| US4200690A (en) * | 1976-12-16 | 1980-04-29 | Millipore Corporation | Immunoassay with membrane immobilized antibody |
| JPS5399319A (en) * | 1977-02-09 | 1978-08-30 | Hidematsu Hirai | Novel qualitative and quantitative detecting method and detecting body for antgenic substance |
| IT1114861B (it) * | 1977-05-12 | 1986-01-27 | Sclavo Inst Sieroterapeut | Metodo per la determinazione del contenuto di costituenti di fluidi biologici e mezzi adatti allo scopo |
| US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| AU531777B2 (en) * | 1978-04-05 | 1983-09-08 | Syva Co. | Label/solid conjugate immunoassay system |
| US4492751A (en) * | 1978-04-10 | 1985-01-08 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing an enzyme substrate as label |
| US4318980A (en) * | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| FR2422956A1 (fr) * | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
| US5605800A (en) * | 1978-04-13 | 1997-02-25 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
| JPS5510590A (en) * | 1978-05-04 | 1980-01-25 | Wellcome Found | Enzyme immunity quantity analysis |
| JPS5539702A (en) * | 1978-08-30 | 1980-03-19 | Takeda Chem Ind Ltd | Method of measuring enzyme immunity of pancreas glucagon |
| FR2440555A1 (fr) * | 1978-10-31 | 1980-05-30 | Maes Roland | Perfectionnements aux procedes de determination de substances montrant entre elles des affinites de liaison specifiques, par des tests faisant intervenir une phase solide |
| US4260678A (en) * | 1979-02-23 | 1981-04-07 | Corning Glass Works | Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes |
| JPS55152459A (en) * | 1979-05-18 | 1980-11-27 | Yamasa Shoyu Co Ltd | Method and reagent for measuring quantity of cyclic nucleotide |
| US4289748A (en) * | 1979-05-31 | 1981-09-15 | United States Of America | Ultrasensitive enzymatic radioimmunoassay method |
| DE2930706A1 (de) * | 1979-07-28 | 1981-02-05 | Medac Klinische Spezialpraep | Verfahren zum nachweis von erregerspezifischen antikoerpern |
| US4299916A (en) * | 1979-12-26 | 1981-11-10 | Syva Company | Preferential signal production on a surface in immunoassays |
| US4394391A (en) * | 1980-02-19 | 1983-07-19 | Thorell Jan Ivan | Radioimmunoassay reagents |
| US4322495A (en) * | 1980-03-11 | 1982-03-30 | Minnesota Mining And Manufacturing Co. | Immunoassay |
| SE8003732L (sv) * | 1980-05-19 | 1981-11-20 | Pharmacia Diagnostics Ab | Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner |
| EP0040728A1 (en) * | 1980-05-19 | 1981-12-02 | Pharmacia Diagnostics Ab | An improvement in and relating to assaying methods involving biospecific affinity reactions |
| JPS5714748A (en) * | 1980-07-01 | 1982-01-26 | Dainippon Pharmaceut Co Ltd | Kit for quantitative determination of valproic acid and its method for quantitative determination |
| US4323647A (en) * | 1980-10-15 | 1982-04-06 | University Of Miami | Steric hindrance enzyme immunoassay |
| DE3048884A1 (de) * | 1980-12-23 | 1982-07-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur enzymimmunobestimmung in heterogener phase |
| ES511156A0 (es) * | 1981-04-13 | 1983-08-01 | Hoechst Co American | Un metodo de determinar la presencia de un antigeno en un medio liquido sospechoso de contenerlo. |
| DE3265823D1 (en) * | 1981-06-02 | 1985-10-03 | Electro Nucleonics | Immunoprecipitation assay |
| US4604365A (en) * | 1981-06-02 | 1986-08-05 | Electro-Nucleonics, Inc. | Immunoprecipitation assay |
| US4506009A (en) * | 1982-03-30 | 1985-03-19 | University Of California | Heterogeneous immunoassay method |
| US4535057A (en) * | 1982-07-26 | 1985-08-13 | Amf Incorporated | Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system |
| US4515890A (en) * | 1982-11-08 | 1985-05-07 | Abbott Laboratories | Immunoassay of terminal deoxynucleotidyl transferase |
| US4650751A (en) * | 1983-04-29 | 1987-03-17 | Technicon Instruments Corporation | Protected binding assay avoiding non-specific protein interference |
| US4778752A (en) * | 1983-10-11 | 1988-10-18 | Scripps Clinic And Research Foundation | Receptors specific for hapten-modified self proteins |
| DE3674567D1 (de) * | 1985-03-18 | 1990-10-31 | Royal Free Hosp School Med | Verbesserungen in bezug auf nachweis von viren und antikoerpern. |
| JPS62148857A (ja) * | 1985-12-24 | 1987-07-02 | Toyo Soda Mfg Co Ltd | 免疫測定用材料の製造方法 |
| EP0247730A3 (en) * | 1986-04-28 | 1989-04-12 | Antibody Technology Limited | Antibodies, their preparation and use and products containing them |
| DE3636724A1 (de) * | 1986-10-29 | 1988-06-23 | Joern Dr Med Kekow | Enzymimmunoassay (elisa) zur insulinbestimmung im mikrotiterplattensystem |
| US6528292B1 (en) * | 1987-05-29 | 2003-03-04 | Aventis Pharmaceuticals Holdings Inc. | Derivatized polystyrene and other polymer supports for spectroscopic studies |
| US5256372A (en) * | 1987-11-06 | 1993-10-26 | Idexx Corporation | Dipstick test device including a removable filter assembly |
| US5137804A (en) * | 1988-05-10 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Assay device and immunoassay |
| US5374524A (en) * | 1988-05-10 | 1994-12-20 | E. I. Du Pont De Nemours And Company | Solution sandwich hybridization, capture and detection of amplified nucleic acids |
| US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
| US5965379A (en) * | 1991-07-19 | 1999-10-12 | Cytimmune Sciences Inc. | Method for measuring endogenous cytokines |
| ATE184703T1 (de) * | 1991-07-19 | 1999-10-15 | Cytimmune Sciences Inc | Verfahren und testsatz zur messung von endogenen zytokinen |
| US5464749A (en) | 1991-07-22 | 1995-11-07 | Bayer Corporation | Immunoassay of free substances in biological fluids |
| US5874423A (en) * | 1992-09-10 | 1999-02-23 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Digitalis-like compounds |
| US5637467A (en) * | 1992-10-13 | 1997-06-10 | Behringwerke Ag | Heterogeneous assay using a pendulous drop |
| WO1995034640A1 (en) * | 1994-06-13 | 1995-12-21 | Henry Ford Health System | A novel neuronal-neonatal gene: neuronatin |
| US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
| US6531277B2 (en) | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
| US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
| US5607565A (en) * | 1995-03-27 | 1997-03-04 | Coulter Corporation | Apparatus for measuring analytes in a fluid sample |
| US5858661A (en) * | 1995-05-16 | 1999-01-12 | Ramot-University Authority For Applied Research And Industrial Development | Ataxia-telangiectasia gene and its genomic organization |
| US5728807A (en) * | 1995-05-16 | 1998-03-17 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Mutated proteins associated with ataxia-telangiectasia |
| US5777093A (en) * | 1995-05-16 | 1998-07-07 | Ramot-University Authority For Applied Research & Industrial Development Ltd. | cDNAs associated with ataxia-telangiectasia |
| US6096508A (en) * | 1995-08-16 | 2000-08-01 | Kirkegaard & Perry Laboratoies, Inc. | Method of reducing background in biotin-based assays |
| US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
| IL134298A0 (en) * | 1997-08-21 | 2001-04-30 | Quark Biotech Inc | Hypoxia-regulating genes |
| US7973156B2 (en) | 1997-08-21 | 2011-07-05 | Quark Pharmaceuticals Inc. | Hypoxia-regulated genes |
| US6284496B1 (en) | 1997-10-03 | 2001-09-04 | University Of South Florida | DNA vector for determining the presence of out-of-reading-frame mutations |
| US6482389B1 (en) | 1997-10-17 | 2002-11-19 | University Of South Florida | Method to diagnose and monitor cellular immune deficiencies |
| US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
| US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
| US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
| US7605149B1 (en) | 1998-07-13 | 2009-10-20 | University Of South Florida | Modulation of the phospholipase A2 pathway as a therapeutic |
| US6187563B1 (en) | 1998-08-07 | 2001-02-13 | Yale University | βIV-spectrin-polypeptides and nucleic acids encoding same |
| BR9914465A (pt) | 1998-09-29 | 2001-10-09 | Gamida Cell Ltd | Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células |
| MXPA01007820A (es) | 1999-02-04 | 2003-06-19 | Technion Res & Dev Foundation | Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras. |
| US6440682B1 (en) * | 1999-05-28 | 2002-08-27 | Detroit R&D Inc. | Detection of hypertension using immunoreactive metabolic products |
| US6787318B1 (en) | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
| US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
| AU5423300A (en) * | 1999-06-25 | 2001-01-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inducing angiogenesis by micro-organs |
| US6875582B1 (en) | 1999-08-19 | 2005-04-05 | Omniscience Pharmaceuticals, Inc. | Methods and targets of antibiotic resistance |
| US7811981B2 (en) * | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| US7101839B1 (en) | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
| EP1230343B1 (en) * | 1999-11-19 | 2006-08-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Aspegillus niger beta-glucosidase gene, protein and uses thereof |
| US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
| WO2001053323A2 (en) * | 2000-01-24 | 2001-07-26 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
| CA2404489A1 (en) | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| IL135884A (en) * | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
| HUP0300810A2 (hu) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
| US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| ES2437093T3 (es) | 2000-08-08 | 2014-01-08 | Technion Research And Development Foundation, Ltd. | Composiciones farmacéuticas y procedimientos útiles para modular la angiogénesis |
| EP1683874A3 (en) | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
| IL155097A0 (en) * | 2000-09-28 | 2003-10-31 | Nanocyte Inc | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| US20070281037A9 (en) * | 2000-09-28 | 2007-12-06 | Nanocyte Inc. | Sterile preparations and compositions including stinging capsules and methods of producing and using same |
| US7632522B2 (en) | 2000-09-28 | 2009-12-15 | Nanocyte Inc. | Use of stinging cells/capsules for the delivery of active agents to keratinous substances |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| CA2429342C (en) | 2000-11-17 | 2013-03-19 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| AU2002218461B2 (en) | 2000-11-24 | 2006-09-07 | Vascular Biogenics Ltd | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US20040106120A1 (en) | 2000-11-30 | 2004-06-03 | Rachid Tazi-Ahnini | Diagnosis and treatment of disease |
| AU2002221013A1 (en) * | 2000-11-30 | 2002-06-11 | Yeda Research And Development Co..Ltd. | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| US20020142287A1 (en) * | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
| US7087395B1 (en) | 2001-01-16 | 2006-08-08 | Quest Diagnostics Investments Incorporated | Vitamin D assay |
| EP1463811A2 (en) * | 2001-01-17 | 2004-10-06 | Ramot at Tel Aviv University Ltd. | Chitinases, derived from carnivorous plants polynucleotide sequences encoding thereof, and methods of isolating and using same |
| WO2002060376A2 (en) * | 2001-01-31 | 2002-08-08 | Tolaren | Induction of tolerance by apoptotic and/or necrotic cells |
| US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
| US20030003454A1 (en) | 2001-03-23 | 2003-01-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer |
| US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
| MXPA04000397A (es) * | 2001-07-19 | 2004-03-18 | Yissum Res Dev Co | Polipeptidos que tienen actividad catalitica de isomerasa de carotenoides, acidos nucleicos que los codifican y usos de los mismos. |
| AU2002330724A1 (en) | 2001-08-16 | 2003-03-10 | Bar Ilan University | Diagnosis, prevention and treatment of cancer |
| US7138144B2 (en) * | 2001-09-07 | 2006-11-21 | Nadir Askenasy | Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation |
| US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| US20060068405A1 (en) * | 2004-01-27 | 2006-03-30 | Alex Diber | Methods and systems for annotating biomolecular sequences |
| KR100866117B1 (ko) | 2001-10-19 | 2008-10-31 | 바스큘라 바이오제닉스 리미티드 | 혈관형성의 표적화 억제조절 및 항암 치료를 위한폴리뉴클레오타이드 작제물, 약학적 조성물 및 방법 |
| AUPR842501A0 (en) * | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| US8178128B2 (en) * | 2001-12-05 | 2012-05-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles containing polymeric nucleic acid homologs |
| US20050085432A1 (en) * | 2001-12-26 | 2005-04-21 | Aviva Lapidot | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
| IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
| US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
| US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
| US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| US20030223994A1 (en) * | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
| WO2003078567A2 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
| DE60320793D1 (de) * | 2002-03-26 | 2008-06-19 | Nanocyte Inc | Nesselzellen mit expression eines exogenen polynucleotids, das ein therapeutisches, diagnostisches oder kosmetisches mittel kodiert, und diese nesselzellen verwendende verfahren, zusammensetzungen und vorrichtungen oder daraus gewonnene kapseln zur ametischen mittels in ein gewebe |
| US20040121442A1 (en) * | 2002-05-05 | 2004-06-24 | Ilan Chet | Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof |
| EP1534345A4 (en) * | 2002-07-12 | 2012-03-21 | Yissum Res Dev Co | METHOD AND DEVICE FOR INDUCING BIOLOGICAL PROCESSES WITH MICROORGANISMS |
| EP1524989B1 (en) | 2002-08-01 | 2013-11-06 | Yeda Research And Development Co., Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| US7267981B2 (en) | 2002-10-07 | 2007-09-11 | Technion Research & Development Foundation Ltd. | Human foreskin fibroblasts for culturing ES cells |
| AU2003284968A1 (en) * | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| EP1578999B1 (en) | 2002-10-30 | 2013-01-16 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for measuring non-transferrin bound iron |
| US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
| AU2003302701A1 (en) * | 2002-11-29 | 2004-06-23 | Technion Research And Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
| US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| SI2338896T1 (sl) | 2002-12-12 | 2015-08-31 | R.B.T. (Rakuto Bio Technologies) Ltd. | Uporaba lignin peroksidaze za posvetlitev kože in las |
| HUE028026T2 (en) | 2002-12-16 | 2016-11-28 | Technion Res & Dev Foundation | Breeding system free of native cells, free of foreign matter for human embryonic stem cells |
| CA2512499A1 (en) | 2003-01-02 | 2004-07-22 | Rappaport Family Institute For Research In The Medical Sciences | Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients |
| EP1583713B1 (en) | 2003-01-07 | 2009-03-25 | Ramot at Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| EP2319857A3 (en) | 2003-03-04 | 2012-06-27 | Yeda Research And Development Co., Ltd. | Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same |
| US20050054103A1 (en) * | 2003-03-07 | 2005-03-10 | Tony Peled | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
| US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
| US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| EP1610678B1 (en) | 2003-04-04 | 2011-07-27 | Yeda Research And Development Co., Ltd. | Antibodies for inhibiting the activity of mmp-2 and mmp-9 |
| WO2004090120A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to sdf-1 and methods of generating and using same |
| FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
| US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
| AU2005234725B2 (en) | 2003-05-22 | 2012-02-23 | Evogene Ltd. | Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby |
| US7554007B2 (en) | 2003-05-22 | 2009-06-30 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants |
| CN100591770C (zh) | 2003-05-22 | 2010-02-24 | 伊沃基因有限公司 | 提高植物非生物胁迫耐受性和/或生物量的方法及用该方法所产生的植物 |
| US20050020499A1 (en) * | 2003-05-27 | 2005-01-27 | Bar Ilan University | Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method |
| US7498428B2 (en) * | 2003-06-19 | 2009-03-03 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
| US8129514B2 (en) * | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
| CA2530927A1 (en) | 2003-06-30 | 2005-01-06 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| US20050271643A1 (en) * | 2003-08-14 | 2005-12-08 | Iryna Sorokulova | Bacterial strains, compositions including same and probiotic use thereof |
| WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
| PT1678209E (pt) | 2003-10-07 | 2011-06-30 | Yeda Res & Dev | Anticorpos para a nik, a sua preparação e a sua utilização |
| CN1918281A (zh) * | 2003-10-23 | 2007-02-21 | 辉瑞产品公司 | 牙周病疫苗 |
| JP5039383B2 (ja) | 2003-11-30 | 2012-10-03 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 免疫モジュレーションのための方法および薬剤ならびに免疫モジュレーターの同定方法 |
| WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
| US20100221233A1 (en) * | 2003-12-15 | 2010-09-02 | University Of South Florida | Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
| DK1722834T3 (da) | 2003-12-22 | 2012-10-22 | Regentis Biomaterials Ltd | Matrix, som omfatter naturligt forekommende tværbundet proteinskelet |
| US8007847B2 (en) | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
| US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
| ES2665463T3 (es) | 2004-06-14 | 2018-04-25 | Evogene Ltd. | Polinucleótidos y polipéptidos implicados en el desarrollo de fibra vegetal y métodos de uso de los mismos |
| US8680062B2 (en) * | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
| WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
| EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS |
| US20060095241A1 (en) * | 2004-10-29 | 2006-05-04 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US8000900B2 (en) | 2004-09-21 | 2011-08-16 | Microsoft Corporation | Association-based predictions of pathogen characteristics |
| EP2357241B1 (en) | 2004-09-29 | 2015-03-04 | Collplant Ltd. | Collagen producing plants and methods of generating and using same |
| BRPI0516302A (pt) * | 2004-09-29 | 2008-09-02 | Yissun Res Dev Company Of The | rnase t2 humana recombinante e suas utilizações |
| WO2006040765A1 (en) * | 2004-10-12 | 2006-04-20 | Closed Loop Therapies Ltd. | Methods and implantable devices for treating supraventricular arrhythmias |
| US8478535B2 (en) | 2004-10-29 | 2013-07-02 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US20060134680A1 (en) * | 2004-12-22 | 2006-06-22 | Alexander Kotlyar | Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof |
| US8375327B2 (en) | 2005-01-16 | 2013-02-12 | Zlango Ltd. | Iconic communication |
| EP1872604A4 (en) * | 2005-01-16 | 2010-01-20 | Zlango Ltd | Communication network system and method for its use |
| WO2007080558A2 (en) * | 2006-01-16 | 2007-07-19 | Zlango Ltd. | Communications network system and methods for using same |
| ES2562406T3 (es) | 2005-01-31 | 2016-03-04 | Realbio Technologies Ltd. | Dispositivo capilar de flujo lateral de reacción multietapa |
| JP4992091B2 (ja) | 2005-02-17 | 2012-08-08 | ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド | 子宮内膜症を治療するためのビスホスホネート |
| US8216801B2 (en) | 2005-02-25 | 2012-07-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), The Volcani Center | Methods for treating inflammatory disorders |
| US7695927B2 (en) * | 2005-03-18 | 2010-04-13 | Detroit R & D | Detection of hypertension using glucuronidated metabolic products |
| US20090068207A1 (en) * | 2005-04-15 | 2009-03-12 | Vascular Biogenics Ltd. | Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease |
| US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
| WO2006116742A2 (en) * | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Fluorescent nanoparticles conjugated to antibodies via a peg linker |
| WO2006116628A2 (en) * | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Enzymes conjugated to antiobodies via a peg heterobifuctional linker |
| WO2006126208A2 (en) | 2005-05-26 | 2006-11-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
| DK1893747T3 (da) | 2005-06-16 | 2014-12-01 | Univ Ramot | Isolerede celler og populationer, der omfatter sådanne celler, til behandling af cns-sygdomme |
| US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| EP2487182B1 (en) | 2005-07-07 | 2019-10-23 | FULCRUM SP Ltd. | Sp1 polypeptides, modified sp1 polypeptides and uses thereof |
| ES2435774T3 (es) | 2005-07-07 | 2013-12-23 | Yissum Research Development Company, Of The Hebrew University Of Jerusalem | Agentes de ácido nucleico para la regulación negativa de H19, y métodos de uso del mismo |
| KR20080038131A (ko) | 2005-07-18 | 2008-05-02 | 프로탈릭스 리미티드 | 생물학적으로 활성인 거대분자의 점막 또는 장관 투여 |
| EP1945755B1 (en) | 2005-07-26 | 2015-01-14 | Rutgers, the State University of New Jersey | Antibody profiles characteristic of tuberculosis state |
| US8642330B2 (en) * | 2005-08-08 | 2014-02-04 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| EP2514315A3 (en) | 2005-08-24 | 2012-11-07 | Yeda Research and Development Co. Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
| WO2007026353A2 (en) | 2005-08-29 | 2007-03-08 | Technion Research & Development Foundation Ltd. | Media for culturing stem cells |
| EP1926814B1 (en) * | 2005-09-22 | 2010-04-28 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
| US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
| BRPI0618965B1 (pt) | 2005-10-24 | 2021-01-12 | Evogene Ltd | método para aumentar a tolerância de uma planta a uma condição de estresse abiótico, método para aumentar a biomassa, vigor e/ou rendimento de uma planta, método para aumentar a eficiência do uso de fertilizante e/ou absorção de uma planta |
| WO2007057967A1 (ja) * | 2005-11-18 | 2007-05-24 | Mitsubishi Denki Kabushiki Kaisha | エレベータのかご照明装置 |
| ES2548518T3 (es) * | 2005-11-23 | 2015-10-19 | Ventana Medical Systems, Inc. | Conjugado molecular |
| EP2390312A1 (en) | 2005-11-29 | 2011-11-30 | Gamida Cell Ltd. | Methods of improving stem cell homing and engraftment |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| US20070134739A1 (en) * | 2005-12-12 | 2007-06-14 | Gyros Patent Ab | Microfluidic assays and microfluidic devices |
| EP2237037A1 (en) | 2005-12-12 | 2010-10-06 | Gyros Patent Ab | Microfluidic device and use thereof |
| EP1977312A2 (en) | 2006-01-16 | 2008-10-08 | Zlango Ltd. | Iconic communication |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| EP1989554A1 (en) | 2006-02-06 | 2008-11-12 | Rappaport Family Institute For Research in the Medical Sciences | Methods and kit for diagnosing t1dm |
| CA2641954C (en) | 2006-03-06 | 2016-04-26 | Zetiq Technologies Ltd. | Methods and compositions for identifying a cell phenotype |
| ES2549528T3 (es) | 2006-03-23 | 2015-10-29 | Pluristem Ltd. | Métodos de expansión de células y usos de células y de medios de acondicionamiento producidos por los mismos para terapia |
| EP2004858A4 (en) | 2006-03-28 | 2009-12-09 | Tel Hashomer Medical Res Infrastructure & Services Ltd | METHOD AND KITS FOR DETERMINING AN INVESTMENT TO WARFARINE RESISTANCE |
| CN101578297A (zh) * | 2006-04-07 | 2009-11-11 | 美国政府健康及人类服务部 | 治疗肿瘤疾病的抗体组合物和方法 |
| MX2008014722A (es) * | 2006-05-19 | 2011-04-15 | Teva Pharma | Proteinas de fusion, usos de las mismas y procesos para producir las mismas. |
| US20070281883A1 (en) * | 2006-06-05 | 2007-12-06 | Hanna Rosenfeld | Development of follicle stimulating hormone agonists and antagonists in fish |
| US8629259B2 (en) | 2006-07-20 | 2014-01-14 | Yeda Research And Development Co. Ltd. | Photosynthetic organisms and compositions and methods of generating same |
| US8809052B2 (en) | 2006-08-28 | 2014-08-19 | Yeda Research And Development Co. Ltd. | Methods of generating mature oligodendrocytes |
| US7888059B2 (en) * | 2006-10-05 | 2011-02-15 | Yeda Research And Development Co. Ltd. | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same |
| EP2079860B1 (en) | 2006-10-05 | 2013-08-07 | Technion Research & Development Foundation Ltd. | Microtubes and methods of producing same |
| AU2007335706B2 (en) * | 2006-12-20 | 2013-03-28 | Evogene Ltd. | Polynucleotides and polypeptides involved in plant fiber development and methods of using same |
| WO2008087642A2 (en) * | 2007-01-16 | 2008-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid constructs and methods for specific silencing of h19 |
| WO2008093331A1 (en) * | 2007-01-29 | 2008-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antibody conjugates for circumventing multi-drug resistance |
| EP2117616A2 (en) | 2007-01-31 | 2009-11-18 | Technion Research & Development Foundation Ltd. | Electrospun scaffolds and methods of generating and using same |
| WO2008093342A2 (en) | 2007-02-01 | 2008-08-07 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
| ES2662036T3 (es) | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Secuencias que se dirigen al núcleo |
| EP2144935A2 (en) | 2007-03-29 | 2010-01-20 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| WO2008120216A1 (en) | 2007-04-02 | 2008-10-09 | Ramot At Tel Aviv University Ltd. | Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease |
| MX2009010858A (es) | 2007-04-09 | 2009-11-02 | Evogene Ltd | Polinucleotidos, polipeptidos y metodos para aumentar el contenido de aceite, la velocidad de crecimiento y biomasa de las plantas. |
| WO2014064687A1 (en) | 2012-10-22 | 2014-05-01 | Deliversir Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
| US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
| EP2144633B1 (en) * | 2007-04-23 | 2014-07-16 | Deliversir Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
| US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
| EP2152905B1 (en) | 2007-05-01 | 2015-12-02 | Tel Hashomer Medical Research Infrastructure and Services Ltd. | Methods and kits for detecting fetal cells in the maternal blood |
| DK3360571T3 (da) | 2007-05-03 | 2021-01-04 | Agency For Science Tech And Research Astarstar | Antistoffer, der binder til et intracellulært PRL-1- eller PRL-3-polypeptid |
| ES2660667T3 (es) | 2007-05-07 | 2018-03-23 | Protalix Ltd. | Biorreactor desechable a gran escala |
| WO2009007980A1 (en) | 2007-07-11 | 2009-01-15 | Yeda Research And Development Co. Ltd. | Nucleic acid construct systems capable of diagnosing or treating a cell state |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| AU2008277257B2 (en) | 2007-07-15 | 2014-03-06 | Hillman, Yitzchak Mr | Disease treatment via antimicrobial peptides or their inhibitors |
| BRPI0812742B1 (pt) | 2007-07-24 | 2021-04-20 | Evogene Ltd | método de aumento da biomassa, da taxa de crescimento, da produtividade de semente, da eficiência do uso de nitrogênio, do estresse abiótico de uma planta, do comprimento de raiz, da cobertura de raiz, da taxa de crescimento da área de roseta, e da taxa de crescimento do diâmetro da roseta de uma planta |
| ES2402334T3 (es) | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
| KR20100071972A (ko) | 2007-08-15 | 2010-06-29 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Mmp-9의 조절인자 및 그의 용도 |
| US8741315B2 (en) | 2007-09-12 | 2014-06-03 | Yeda Research And Development Co. Ltd. | Methods of treating tumors in immune-privileged sites |
| KR20140107677A (ko) | 2007-09-19 | 2014-09-04 | 플루리스템 리미티드 | 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도 |
| WO2009050691A2 (en) | 2007-10-19 | 2009-04-23 | Rappaport Family Institute For Research In The Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| US8431158B2 (en) | 2007-11-26 | 2013-04-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions comprising fibrous polypeptides and polysaccharides |
| CA2709517C (en) | 2007-12-27 | 2019-02-26 | Evogene Ltd. | Isolated polypeptides, polynucleotides useful for modifying water use efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants |
| AU2009208607B2 (en) * | 2008-01-31 | 2013-08-01 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| ES2483465T3 (es) | 2008-02-21 | 2014-08-06 | Technion Research And Development Foundation, Ltd. | Uso de microtubos de electro-hilado para suministrar un fármaco |
| US8747855B2 (en) * | 2008-04-09 | 2014-06-10 | Technion Research & Development Foundation Limited | Anti human immunodeficiency antibodies and uses thereof |
| US20110033473A1 (en) * | 2008-04-09 | 2011-02-10 | Yoram Reiter | Anti influenza antibodies and uses thereof |
| EP2508325A3 (en) * | 2008-04-10 | 2013-05-22 | Objet Ltd. | System and method for three dimensional model printing |
| WO2009128076A2 (en) | 2008-04-18 | 2009-10-22 | Collplant Ltd. | Methods of generating and using procollagen |
| ES2551318T3 (es) | 2008-04-21 | 2015-11-18 | Danziger Innovations Ltd. | Vectores de expresión virales de plantas y uso de los mismos para generar variaciones genotípicas en genomas de plantas |
| JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| CA2724545C (en) | 2008-05-22 | 2018-12-11 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
| WO2009144720A1 (en) | 2008-05-27 | 2009-12-03 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
| US8663987B2 (en) | 2008-05-28 | 2014-03-04 | Ramot At Tel-Aviv University Ltd. | Mesenchymal stem cells for the treatment of CNS diseases |
| WO2010007613A1 (en) | 2008-06-29 | 2010-01-21 | Realbio Technologies Ltd. | Liquid–transfer device particularly useful as a capturing device in a biological assay process |
| US9580513B2 (en) | 2008-08-08 | 2017-02-28 | Agency For Science, Technology And Research (A*Star) | VHZ for diagnosis and treatment of cancers |
| JP5583667B2 (ja) | 2008-08-08 | 2014-09-03 | ジェニスフィア・エルエルシー | 長時間作用型dnaデンドリマーおよびその方法 |
| US9018445B2 (en) | 2008-08-18 | 2015-04-28 | Evogene Ltd. | Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant |
| MX2011002328A (es) | 2008-09-02 | 2011-05-19 | Pluristem Ltd | Celulas adherentes del tejido de placenta y su uso en terapia. |
| US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
| WO2010029545A2 (en) | 2008-09-11 | 2010-03-18 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and methods for treating s. pneumoniae infection |
| BRPI0919020B8 (pt) | 2008-09-12 | 2021-05-25 | Cryopraxis Criobiologia Ltda | uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris |
| CN104892728A (zh) | 2008-09-24 | 2015-09-09 | 特尔哈肖梅尔医学研究基础设施和服务有限公司 | 用于防止细胞粘附的肽和组合物及其使用方法 |
| WO2010035261A2 (en) | 2008-09-29 | 2010-04-01 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
| WO2012032526A2 (en) | 2010-09-08 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment |
| MX345298B (es) * | 2008-10-30 | 2017-01-24 | Evogene Ltd | Polinucleótidos y polipéptidos aislados y métodos para utilizarlos para aumentar el rendimiento de la planta, biomasa, tasa de crecimiento, vigor, contenido de aceite, tolerancia al estrés abiótico de las plantas y eficacia en el uso de nitrógeno. |
| WO2010055525A1 (en) | 2008-11-17 | 2010-05-20 | Technion Research & Development Foundation Ltd. | Method for predicting a patient's responsiveness to anti-folate therapy |
| WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
| WO2010061383A1 (en) | 2008-11-26 | 2010-06-03 | Biodalia Microbiological Technologies Ltd. | A method of in-situ enrichment of foods with fructan |
| WO2010064231A1 (en) | 2008-12-02 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of analyzing a-i rna editing and nucleic acid constructs capable of same |
| US20120014927A1 (en) | 2008-12-03 | 2012-01-19 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
| EP2373301B1 (en) | 2008-12-05 | 2013-11-06 | Yeda Research and Development Co. Ltd. | Methods of diagnosing motor neuron diseases |
| WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
| EP2808402A3 (en) | 2008-12-29 | 2015-03-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment |
| EP2373792B1 (en) | 2008-12-29 | 2016-11-02 | Evogene Ltd. | Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same |
| ES2528133T3 (es) | 2008-12-29 | 2015-02-04 | Tel Hashomer Medical Research, Infrastructure And Services Ltd. | Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos |
| WO2010076794A1 (en) | 2008-12-31 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Method of denitrifying brine and systems capable of same |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| IL196820A0 (en) | 2009-02-01 | 2009-11-18 | Yissum Res Dev Co | Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells |
| CN102369015A (zh) | 2009-02-02 | 2012-03-07 | 雷蒙特亚特特拉维夫大学有限公司 | 肽、包含该肽的药物组合物及其用途 |
| WO2010089707A1 (en) | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
| US8828722B2 (en) | 2009-02-26 | 2014-09-09 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Isolated populations of renal stem cells and methods of isolating and using same |
| HUE041819T2 (hu) | 2009-03-02 | 2019-05-28 | Evogene Ltd | Izolált polinukleotidek és polipeptidek, és azok alkalmazási eljárásai növényhozam és/vagy mezõgazdasági jellemzõk fokozására |
| US8546330B2 (en) | 2009-03-09 | 2013-10-01 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for treatment of neurodegenerative diseases |
| WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| WO2010113096A1 (en) | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
| WO2010113146A1 (en) | 2009-04-01 | 2010-10-07 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | A method of regulating proliferation and differentiation of keratinocyes |
| WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
| PL2990421T3 (pl) | 2009-04-30 | 2018-08-31 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Przeciwciała anty-ceacam1 oraz sposoby ich stosowania |
| WO2010134073A1 (en) | 2009-05-19 | 2010-11-25 | Zetiq Technologies Ltd. | Kits for and methods of differential staining of cervical cancer cells and/or tissues |
| EP2435072A2 (en) | 2009-05-27 | 2012-04-04 | Yeda Research and Development Co. Ltd. | Proteasome inhibitors and uses thereof |
| WO2010137013A1 (en) | 2009-05-27 | 2010-12-02 | Ramot At Tel Aviv University Ltd. | Crystallized photosystem i units from the pea plant and their use in solid state devices |
| WO2010137021A2 (en) | 2009-05-27 | 2010-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
| EP2435078A1 (en) | 2009-05-28 | 2012-04-04 | Yeda Research and Development Co. Ltd. | Methods of treating inflammation |
| EP3238534B1 (en) | 2009-06-10 | 2019-11-13 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance |
| WO2010150259A1 (en) | 2009-06-24 | 2010-12-29 | Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical Center | Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders |
| WO2013121416A1 (en) | 2012-02-14 | 2013-08-22 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
| AU2010274581B2 (en) | 2009-07-21 | 2014-05-01 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A method of diagnosing cancer |
| GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| US20120148546A1 (en) | 2009-08-17 | 2012-06-14 | Technion Research & Development Foundation Ltd. | Pericyte progenitor cells and methods of generating and using same |
| SG178845A1 (en) | 2009-08-21 | 2012-04-27 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
| BR112012008078A2 (pt) | 2009-08-21 | 2017-07-04 | Beeologics Inc | prevenção e cura de doenças de inseto benéfico por meio de moléculas transcritas de planta. |
| US20110207144A1 (en) * | 2009-08-21 | 2011-08-25 | Derek Marshall | In vitro screening assays |
| US9642817B2 (en) | 2009-08-27 | 2017-05-09 | Technion Research & Development Foundation Limited | Liposomal compositions and uses of same |
| WO2011030336A1 (en) | 2009-09-08 | 2011-03-17 | Ramot At Tel-Aviv University Ltd. | Methods of diagnosing amyotrophic lateral sclerosis (als) |
| US9610331B2 (en) | 2009-09-08 | 2017-04-04 | Yeda Research And Development Co. Ltd. | Methods for hematopoietic precursor mobilization |
| US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
| JP2013505230A (ja) | 2009-09-17 | 2013-02-14 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 酸化ストレス関連障害を処置するためのペプチド |
| EP2478093A2 (en) | 2009-09-17 | 2012-07-25 | Yeda Research and Development Co. Ltd. | Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
| US8735124B2 (en) | 2009-09-17 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
| US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| MX353880B (es) | 2009-10-14 | 2018-01-31 | Yissum Research Development Company Of The Hebrew Univ Of Jerusalem Ltd Star | Composiciones para controlar ácaros varroa en abejas. |
| CA2777663A1 (en) | 2009-10-16 | 2011-04-21 | University Of Medicine And Dentistry Of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
| US9476060B2 (en) | 2009-10-21 | 2016-10-25 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
| IL201999A (en) | 2009-11-08 | 2017-10-31 | Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel | A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity |
| WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
| EP2498806B1 (en) | 2009-11-12 | 2014-12-31 | Ramot at Tel-Aviv University Ltd. | Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes |
| EP4166652A1 (en) | 2009-11-12 | 2023-04-19 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| US20120230974A1 (en) | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
| WO2011064773A1 (en) | 2009-11-24 | 2011-06-03 | Collplant Ltd. | Method of generating collagen fibers |
| ES2553712T3 (es) | 2009-11-30 | 2015-12-11 | Pluristem Ltd. | Células adherentes de la placenta y uso de las mismas en el tratamiento de enfermedad |
| WO2011067745A2 (en) | 2009-12-06 | 2011-06-09 | Rosetta Green Ltd. | Compositions and methods for enhancing plants resistance to abiotic stress |
| EP2862929B1 (en) | 2009-12-09 | 2017-09-06 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating diseases, disorders or injury of the CNS |
| AR081095A1 (es) | 2009-12-28 | 2012-06-13 | Evogene Ltd | Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para aumentar el rendimiento de la planta, biomasa, tasa de crecimiento, vigor, contenido de aceite, tolerancia al estres abiotico y eficacia en el uso de nitrogeno |
| DK3184109T3 (da) | 2009-12-29 | 2021-02-15 | Gamida Cell Ltd | Fremgangsmåder til forbedring af natural killer-cellers proliferation og aktivitet |
| NZ601324A (en) | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| JP6009357B2 (ja) | 2010-01-12 | 2016-10-19 | バスキュラー バイオジェニックス リミテッド | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 |
| EA201270701A1 (ru) | 2010-01-27 | 2013-01-30 | Йеда Рисеч Энд Девелопмент Ко. Лтд. | Ингибирующие металлопротеины антитела |
| BR112012019693A2 (pt) | 2010-02-04 | 2017-06-20 | Gilead Biologics Inc | anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles. |
| WO2011099006A2 (en) | 2010-02-11 | 2011-08-18 | Yeda Research And Development Co. Ltd. | Enzymatic systems for carbon fixation and methods of generating same |
| WO2011104708A2 (en) | 2010-02-24 | 2011-09-01 | Ben Gurion University Of The Negev Research And Development Authority | Methods for inhibiting necrosis |
| WO2011107939A1 (en) | 2010-03-01 | 2011-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors |
| WO2011107994A1 (en) | 2010-03-04 | 2011-09-09 | Yeda Research And Development Co. Ltd. | Methods of measuring protein stability |
| WO2011111034A1 (en) | 2010-03-08 | 2011-09-15 | Yeda Research And Development Co. Ltd. | Recombinant protein production in heterologous systems |
| PL2545182T4 (pl) | 2010-03-08 | 2017-11-30 | Monsanto Technology Llc | Cząsteczki polinukeotydu do regulacji genów w roślinach |
| CN102918159A (zh) | 2010-03-11 | 2013-02-06 | 雅各布·埃德尔 | 产生氢的方法 |
| US9073990B2 (en) | 2010-04-05 | 2015-07-07 | Bar-Llan University | Protease-activatable pore-forming polypeptides |
| WO2011128895A2 (en) | 2010-04-12 | 2011-10-20 | Ben Gurion University Of The Negev Research And Development Authority | Sulfotransferase of a red microalga and uses thereof |
| WO2011128897A1 (en) | 2010-04-12 | 2011-10-20 | Technion Research & Development Foundation Ltd. | Populations of pancreatic progenitor cells and methods of isolating and using same |
| US9518988B2 (en) | 2010-04-18 | 2016-12-13 | Yeda Research And Development Co. Ltd. | Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases |
| BR122021002353B1 (pt) | 2010-04-28 | 2022-08-16 | Evogene Ltd | Método de aumento de produção, biomassa, taxa de crescimento, vigor, tolerância ao estresse abiótico e/ou eficiência de uso de nitrogênio de uma planta, e, construto de ácido nucleico isolado |
| US20130053277A1 (en) | 2010-05-04 | 2013-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
| EP2566500B1 (en) | 2010-05-05 | 2017-04-12 | Rappaport Family Institute for Research in the Medical Sciences | Ccl1 for use in therapy |
| IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
| CA2799307C (en) | 2010-05-13 | 2019-07-02 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Isolated populations of adult renal cells and methods of isolating and using same |
| DK2390664T3 (da) | 2010-05-25 | 2013-07-22 | Fraunhofer Ges Forschung | Fremgangsmåde til elektrokemisk påvisning af bindingsreaktioner |
| CA2800257C (en) | 2010-05-26 | 2019-03-05 | The Board Of Trustees Of The University Of Illinois | Personal glucose meters for detection and quantification of a broad range of analytes |
| EP2575859B1 (en) | 2010-06-03 | 2018-09-19 | Ramot at Tel Aviv University, Ltd. | Methods of treating diabetes and compositions capable of same |
| KR20130123357A (ko) | 2010-06-07 | 2013-11-12 | 오스나트 에슈어-파비안 | 저산소증과 관련된 질환의 진단방법 및 키트 |
| BR112012032126A2 (pt) | 2010-06-16 | 2017-10-17 | Futuragene Israel Ltd Empresa Isralense | polinucleotídeo isolado, estrutura de ácido nucléico, sistema de estrutura de ácido nucléico, polipeptídeo isolado, planta, composição inseticida, e método para controlar ou exterminar um inseto |
| EP2582842A2 (en) | 2010-06-16 | 2013-04-24 | Yissum Research Development Company of The Hebrew University of Jerusalem | Method of diagnosing and treating cancer |
| ES2817780T3 (es) | 2010-07-12 | 2021-04-08 | The State Of Israel Ministry Of Agriculture And Rural Development Agricultural Res Organization A R | Polinucleótidos aislados y métodos y plantas que usan los mismos para regular la acidez de las plantas |
| JP2013538555A (ja) | 2010-07-15 | 2013-10-17 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | Mhcクラスiiとグルタミン酸デカルボキシラーゼ(gad)自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体 |
| US20130189284A1 (en) | 2010-07-15 | 2013-07-25 | Technion Research & Development Foundation Ltd. | Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
| CA2804728A1 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Nucleic acid construct for increasing abiotic stress tolerance in plants |
| CA2804914A1 (en) | 2010-07-22 | 2012-01-26 | Nadir Askenasy | Regulatory immune cells with enhanced targeted cell death effect |
| US9144585B2 (en) | 2010-07-27 | 2015-09-29 | Technion Research & Development Foundation Limited | Isolated mesenchymal progenitor cells and extracellular matrix produced thereby |
| WO2012014207A2 (en) | 2010-07-27 | 2012-02-02 | Technion Research & Development Foundation Ltd. | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
| US20130130311A1 (en) | 2010-07-27 | 2013-05-23 | Yeda Research And Development Co., Ltd. | Methods and systems for assessing clonality of cell cultures |
| WO2012017439A2 (en) | 2010-08-04 | 2012-02-09 | Ramot At Tel-Aviv University Ltd. | Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases |
| US9394523B2 (en) | 2010-08-22 | 2016-07-19 | Ramot At Tel-Aviv University Ltd. | Induced pluripotent stem cells derived from human pancreatic beta cells |
| WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
| CA3158003A1 (en) | 2010-08-30 | 2012-03-08 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance |
| US20130164288A1 (en) | 2010-09-07 | 2013-06-27 | Protalix Ltd. | Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease |
| WO2012032510A1 (en) | 2010-09-07 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Primers for amplifying dna and methods of selecting same |
| WO2012032519A2 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing parkinson's disease |
| US10214722B2 (en) | 2010-09-07 | 2019-02-26 | Technion Research & Development Foundation Limited | Methods for expanding and maintaining human pluripotent stem cells (PSCs) in an undifferentiated state in a single cell suspension culture |
| CA2810631A1 (en) | 2010-09-08 | 2012-03-15 | Yeda Research And Development Co. Ltd. | An immunosuppressive drug combination for a stable and long term engraftment |
| CN103210082A (zh) | 2010-09-15 | 2013-07-17 | 雷蒙特亚特特拉维夫大学有限公司 | 扩增胰岛β细胞和使其再分化的方法 |
| WO2012038956A1 (en) | 2010-09-20 | 2012-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
| EP3075396A1 (en) | 2010-10-17 | 2016-10-05 | Yeda Research and Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
| WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
| US20130216603A1 (en) | 2010-10-27 | 2013-08-22 | Nanocyte (Israel) Ltd. | Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
| CN103370337B (zh) | 2010-10-28 | 2015-12-09 | 耶达研究及发展有限公司 | 用于产生针对金属酶的抗体的方法 |
| BR112013010825A2 (pt) | 2010-11-03 | 2019-09-24 | Futuragene Israel Ltda | plantas transgênicas com rendimentos melhorados de sacarificação e métodos para geração das mesmas |
| EP2635105B1 (en) | 2010-11-04 | 2017-12-20 | Ben-Gurion University of The Negev Research and Development Authority | Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof |
| AU2011330768A1 (en) | 2010-11-15 | 2013-05-30 | Merz Pharma Gmbh & Co. Kgaa | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
| US10117895B2 (en) | 2010-11-17 | 2018-11-06 | Ben-Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
| US9574171B2 (en) | 2010-12-02 | 2017-02-21 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
| AU2011253984A1 (en) | 2010-12-07 | 2012-06-28 | Biobalance Llc | Method For Identifying E. Coli M-17 |
| EP2652125B1 (en) | 2010-12-15 | 2017-04-26 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
| MX344728B (es) | 2010-12-22 | 2017-01-05 | Evogene Ltd | Polinucleótidos y polipéptidos aislados, y métodos para utilizarlos para aumentar la tolerancia al estrés abiótico, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o eficacia en el uso de nitrógeno de las plantas. |
| ES2645245T3 (es) | 2010-12-28 | 2017-12-04 | Kamedis Ltd. | Extractos vegetales para el tratamiento y prevención de infecciones |
| BR112013018516B1 (pt) | 2011-01-20 | 2023-11-07 | Protalix Ltd | Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição |
| WO2012104851A1 (en) | 2011-01-31 | 2012-08-09 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
| WO2012114339A1 (en) | 2011-02-23 | 2012-08-30 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
| CN103597078B (zh) | 2011-03-02 | 2016-12-14 | 富途锐基尼以色列有限公司 | 具有功能失调的t3ss蛋白的抗菌性转基因植物 |
| US9365828B2 (en) | 2011-03-03 | 2016-06-14 | Ramot At Tel-Aviv University Ltd. | Genetically modified muscle cells which express neurotrophic factors |
| WO2012120500A2 (en) | 2011-03-06 | 2012-09-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| US9061006B2 (en) | 2011-03-08 | 2015-06-23 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (PKU) |
| CN103429619B (zh) | 2011-03-17 | 2017-07-28 | 雷蒙特亚特特拉维夫大学有限公司 | 双特异性和单特异性、不对称抗体和其制备方法 |
| CN103533934B (zh) | 2011-03-17 | 2016-03-30 | 特尔汗什莫尔医学基础设施研究和服务公司 | 用于治疗自身免疫性疾病的喹诺酮类似物 |
| EP3260533B1 (en) | 2011-03-22 | 2019-09-11 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
| EP2688582B1 (en) | 2011-03-24 | 2017-02-15 | Neurim Pharmaceuticals (1991) Limited | Neuroprotective peptides |
| WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
| WO2012137202A1 (en) | 2011-04-05 | 2012-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci) |
| CA2832031C (en) | 2011-04-06 | 2019-09-17 | Ramot At Tel-Aviv University Ltd. | Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| MX349171B (es) | 2011-04-15 | 2017-07-17 | Pluristem Ltd | Metodos y sistemas para cosechar celulas. |
| BR122020018201B1 (pt) | 2011-05-03 | 2021-11-09 | Evogene Ltd | Métodos para aumentar o rendimento, biomassa, taxa de crescimento, vigor, conteúdo de óleo, rendimento de fibra, qualidade da fibra, tolerância ao estresse abiótico e/ou eficiência no uso de nitrogênio de uma planta, para gerar uma planta transgênica, e, construto de ácido nucléico |
| EP2704793B1 (en) | 2011-05-04 | 2019-07-17 | Ramot at Tel Aviv University, Ltd. | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease |
| WO2012153333A1 (en) | 2011-05-09 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Regeneration and repair of mesenchymal tissue using amelogenin |
| WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
| WO2012156976A1 (en) | 2011-05-16 | 2012-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of producing artemisinin in non-host plants and vectors for use in same |
| US20140088017A1 (en) | 2011-05-23 | 2014-03-27 | Yeda Research And Development Co., Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| WO2012160526A2 (en) | 2011-05-23 | 2012-11-29 | Ofir Menashe | Formulations of microorganism comprising particles and uses of same |
| CN107325165A (zh) | 2011-05-31 | 2017-11-07 | 和黄生物膜医疗解决方案有限公司 | 细胞聚集体的分散和脱离 |
| WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| WO2012172555A1 (en) | 2011-06-14 | 2012-12-20 | Yeda Research And Development Co. Ltd. | Combination therapy to prevent dcis formation and progression to breast cancer |
| KR20140058506A (ko) | 2011-06-23 | 2014-05-14 | 카이마 바이오 아그리테크 리미티드 | 부분적으로 또는 완전히 다중화된 게놈을 가지는 보통계 밀 식물 또는 이의 부분물, 이의 하이브리드와 생성물, 및 이를 생성 및 사용하는 방법 |
| EP2734036A1 (en) | 2011-07-20 | 2014-05-28 | Kaiima Bio Agritech Ltd. | Maize plants having a partially or fully multiplied genome and uses thereof |
| EP2550982A1 (en) | 2011-07-27 | 2013-01-30 | Technion Research & Development Foundation Ltd. | Devices for surgical applications |
| JP6309450B2 (ja) | 2011-08-04 | 2018-04-11 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロrnaおよび該ミクロrnaを含む組成物 |
| WO2013021389A2 (en) | 2011-08-09 | 2013-02-14 | Yeda Research And Development Co.Ltd. | Downregulation of mir-7 for promotion of beta cell differentiation and insulin production |
| RU2014108930A (ru) | 2011-08-14 | 2015-09-20 | Каиима Био Агритех Лтд. | Растения твердой пшеницы, обладающие частично или полностью умноженным геномом, и их применения |
| EP2753367A4 (en) | 2011-09-07 | 2015-10-14 | Yeda Res & Dev | OLFACTORY SIGNATURE AND ODORING MIXTURE THEREWITH |
| AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| US20140248293A1 (en) | 2011-09-08 | 2014-09-04 | Yeda Research And Development Co., Ltd | Novel risk biomarkers for lung cancer |
| EP2755988B1 (en) | 2011-09-13 | 2018-08-22 | Monsanto Technology LLC | Methods and compositions for weed control |
| UA115535C2 (uk) | 2011-09-13 | 2017-11-27 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| CA2848680C (en) | 2011-09-13 | 2020-05-19 | Monsanto Technology Llc | Methods and compositions for weed control |
| MX377067B (es) | 2011-09-13 | 2025-03-07 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas. |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| PT2768851T (pt) | 2011-10-21 | 2017-09-08 | Augurex Life Sciences Corp | Antigénios derivados de 14-3-3 citrulinada e utilizações dos mesmos no diagnóstico de artrite reumatoide |
| EP2771464B1 (en) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Methods of treating cancer |
| SG11201401648RA (en) | 2011-11-03 | 2014-05-29 | Quark Pharmaceuticals Inc | Methods and compositions for neuroprotection |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| WO2013076729A1 (en) | 2011-11-23 | 2013-05-30 | Danziger Dan Flower Farm | Otomeria plants |
| WO2013076730A1 (en) | 2011-11-27 | 2013-05-30 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis and compositions capable of same |
| ES2673471T3 (es) | 2011-12-08 | 2018-06-22 | Yeda Research And Development Co. Ltd. | Células pulmonares fetales de mamífero y uso terapéutico de las mismas |
| WO2013093921A1 (en) | 2011-12-20 | 2013-06-27 | Collplant Ltd. | Collagen coated synthetic polymer fibers |
| MX2014007648A (es) | 2011-12-22 | 2015-03-19 | Yeda Res & Dev | Una terapia de combinacion para un injerto estable y a largo plazo usando protocolos especificos para agotamiento de celulas t/b. |
| CN104254395B (zh) | 2011-12-22 | 2016-05-04 | 生命科技公司 | 用于分析物测定的序贯侧向流动毛细管装置 |
| CN104270939A (zh) | 2011-12-28 | 2015-01-07 | 凯伊玛生物农业科技有限公司 | 具有部分加倍或完全加倍的基因组的栽培高粱植物及其应用 |
| JP2015509085A (ja) | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. | 治療剤および診断剤の選択的送達のためのendo180を標的とする粒子 |
| WO2013114363A2 (en) | 2012-01-30 | 2013-08-08 | Yeda Research And Development Co.Ltd. | Antimicrobial agents |
| US9603906B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Inhalable liquid formulations of DNase I |
| US10184131B2 (en) | 2012-02-06 | 2019-01-22 | A.B. Seeds Ltd. | Isolated polynucleotides expressing or modulating microRNAs or targets of same, transgenic plants comprising same and uses thereof |
| BR112014020119A2 (pt) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | cultura de células-tronco mesenquimais |
| WO2013121405A1 (en) | 2012-02-19 | 2013-08-22 | Protalix Ltd. | Oral unit dosage forms and uses of same for the treatment of gaucher disease |
| US10034902B2 (en) | 2012-02-22 | 2018-07-31 | Exostem Biotec Ltd. | MicroRNAs for the generation of astrocytes |
| EP2844745A2 (en) | 2012-02-22 | 2015-03-11 | Brainstem Biotec Ltd. | Generation of neural stem cells and motor neurons |
| EP2833714A1 (en) | 2012-03-01 | 2015-02-11 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Male sterile garlic plants, hybrid offspring of same and methods of generating and using same |
| CA2865486C (en) | 2012-03-07 | 2021-03-30 | Yeda Research And Development Co. Ltd. | Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same |
| WO2013140389A1 (en) | 2012-03-22 | 2013-09-26 | Ramot At Tel-Aviv University Ltd. | Plif multimeric peptides and uses thereof |
| CN104271749A (zh) | 2012-04-18 | 2015-01-07 | 雷蒙特亚特特拉维夫大学有限公司 | 用于递送核酸的脂化的糖胺聚糖颗粒 |
| JP2015520128A (ja) | 2012-04-19 | 2015-07-16 | オプコ バイオロジクス リミテッド | 長時間作用性オキシントモジュリン変異体とその作製方法 |
| WO2013160895A1 (en) | 2012-04-24 | 2013-10-31 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| ES2627816T3 (es) | 2012-05-09 | 2017-07-31 | Yeda Research And Development Co. Ltd. | Variantes del pro-dominio de tace como inhibidor de TNF-a y su uso médico |
| US8865158B2 (en) | 2012-05-22 | 2014-10-21 | Ramot At Tel-Aviv University Ltd. | Bacteriophages for reducing toxicity of bacteria |
| CN104603149B (zh) | 2012-05-24 | 2017-06-30 | 万机集团有限公司 | 与预防和治疗狂犬病感染相关的组合物和方法 |
| AR091143A1 (es) | 2012-05-24 | 2015-01-14 | Seeds Ltd Ab | Composiciones y metodos para silenciar la expresion genetica |
| EP2855507B1 (en) | 2012-06-03 | 2018-01-03 | Ben-Gurion University of The Negev Research and Development Authority | Functionalized titanium binding peptides and implants coated with same |
| KR102092025B1 (ko) | 2012-06-04 | 2020-03-24 | 옵코 바이오로직스 리미티드 | 페길화된 옥신토모둘린 변이체 |
| WO2014006621A1 (en) | 2012-07-03 | 2014-01-09 | Nanospun Technologies Ltd. | Methods and devices for adsorption and biodegradation of petroleum |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| EP2880155B1 (en) | 2012-07-29 | 2019-04-17 | Yeda Research and Development Co., Ltd. | Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms |
| JP6340366B2 (ja) | 2012-07-31 | 2018-06-06 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 運動ニューロン疾患を診断および処置する方法 |
| EP2880151B1 (en) | 2012-08-06 | 2020-06-03 | Brainstorm Cell Therapeutics Ltd. | Methods of generating mesenchymal stem cells which secrete neurotrophic factors |
| US20140068814A1 (en) | 2012-09-03 | 2014-03-06 | A.B. Seeds Ltd. | Method of improving abiotic stress tolerance of plants and plants generated thereby |
| US10543278B2 (en) | 2012-09-12 | 2020-01-28 | Ramot At Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
| EP2906954B1 (en) | 2012-10-09 | 2018-04-11 | Ramot at Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
| WO2014064682A1 (en) | 2012-10-24 | 2014-05-01 | Yeda Research And Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
| US9926564B2 (en) | 2012-10-29 | 2018-03-27 | Yeda Research And Development Co. Ltd. | Aptamers, multimeric aptamers and uses thereof |
| ES2882890T3 (es) | 2012-11-20 | 2021-12-03 | Opko Biologics Ltd | Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina |
| BR112015002626A2 (pt) | 2012-11-29 | 2017-09-26 | Yeda Res & Dev | métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa |
| WO2015079413A2 (en) | 2013-11-28 | 2015-06-04 | Yeda Research And Development Co. Ltd. | Synaptojanin-2 inhibitors and uses thereof |
| CN105358695B (zh) | 2013-01-01 | 2019-07-12 | A.B.种子有限公司 | 将dsRNA引入植物种子以调节基因表达的方法 |
| US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
| WO2014108850A2 (en) | 2013-01-09 | 2014-07-17 | Yeda Research And Development Co. Ltd. | High throughput transcriptome analysis |
| WO2014111936A1 (en) | 2013-01-17 | 2014-07-24 | Novellusdx Ltd. | Methods and systems for identifying patient specific driver mutations |
| US10000737B2 (en) | 2013-02-04 | 2018-06-19 | Ramot At Tel-Aviv University Ltd. | Generation of cytotoxic tumor specific cell lines and uses thereof |
| EP2964669B1 (en) | 2013-03-06 | 2018-09-12 | Protalix Ltd. | Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy |
| US20160017021A1 (en) | 2013-03-06 | 2016-01-21 | Protalix Ltd. | TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME |
| UA121846C2 (uk) | 2013-03-13 | 2020-08-10 | Монсанто Текнолоджи Ллс | Спосіб та гербіцидна композиція для контролю видів рослини роду lolium |
| EP2971185A4 (en) | 2013-03-13 | 2017-03-08 | Monsanto Technology LLC | Methods and compositions for weed control |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| JP6346265B2 (ja) | 2013-03-21 | 2018-06-20 | ジェニスフィア・エルエルシー | Dnaインターカレーティング剤の細胞送達 |
| CN105263511A (zh) | 2013-03-21 | 2016-01-20 | 科尔普兰特有限公司 | 用于组织再生的包含胶原和prp的组合物 |
| JP6294459B2 (ja) | 2013-03-24 | 2018-03-14 | バイオカイン・セラピューティクス・リミテッドBiokine Therapeutics Ltd. | 骨髄性白血病の処置方法 |
| CA2909380A1 (en) | 2013-04-21 | 2014-10-30 | Yeda Research And Development Co. Ltd. | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w |
| JP2016521971A (ja) | 2013-04-23 | 2016-07-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法119条第(e)項に基づき、2014年1月29日出願の米国特許仮出願第61/932,935号、2013年9月17日出願の米国特許仮出願第61/878,769号、および2013年4月23日出願の米国特許仮出願第61/814,920号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、YaqubHANNA、NoaNOVERSHTERN、およびYoachRAISによる米国特許出願(発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法(ISOLATEDNAIVEPLURIPOTENTSTEMCELLSANDMETHODSOFGENERATINGSAME)」)(代理人事件記録簿第58870号)にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。 |
| WO2014174520A1 (en) | 2013-04-25 | 2014-10-30 | Yeda Research And Development Co. Ltd. | Use of inhibitory peptides for the treatment of inflammatory diseases |
| WO2014188423A1 (en) | 2013-05-21 | 2014-11-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
| JP6622190B2 (ja) | 2013-05-27 | 2019-12-18 | ラクト・バイオ・テクノロジーズ・リミテッド | 酵素系含有化粧品組成物 |
| EP3013380B1 (en) | 2013-06-24 | 2022-11-23 | Ramot at Tel-Aviv University Ltd. | Omentum based scaffold and delivery system |
| MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
| US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
| US9938316B2 (en) | 2013-08-29 | 2018-04-10 | Yeda Research And Development Co. Ltd. | Selective inhibitors of α2 isoform of Na,K-ATPase and use thereof for reduction of intra-ocular pressure and as cardiotonic agents |
| IL228284A (en) | 2013-09-03 | 2016-12-29 | Technion Res & Dev Foundation | Implants from cellular scaffolding and blood vessel stalk |
| WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
| WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
| WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
| EP3046929B1 (en) | 2013-09-17 | 2019-01-16 | Yeda Research and Development Co., Ltd. | Erk-derived peptides and uses thereof |
| WO2015049677A1 (en) | 2013-10-01 | 2015-04-09 | Kadimastem Ltd. | Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als) |
| EP3055066A4 (en) | 2013-10-07 | 2017-06-14 | Yeda Research and Development Co., Ltd. | Microfluidic device for analyzing gene expression |
| SI3060239T1 (sl) | 2013-10-21 | 2020-10-30 | Opko Bilogics Ltd | Dolgodelujoči polipeptidi ter postopki za proizvodnjo in dajanje le-teh |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10767156B2 (en) | 2013-10-24 | 2020-09-08 | Yeda Research And Development Co., Ltd. | Polynucleotides encoding BREX system polypeptides and methods of using same |
| CA2928315C (en) | 2013-10-31 | 2023-03-21 | Biokine Therapeutics Ltd. | Methods of treating acute myeloid leukemia with a flt3 mutation |
| UY35817A (es) | 2013-11-04 | 2015-05-29 | Us Agriculture | ?composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos?. |
| WO2015079411A1 (en) | 2013-11-28 | 2015-06-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
| EP3080243B1 (en) | 2013-12-10 | 2018-09-05 | Yeda Research and Development Co., Ltd. | Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-coa and bacteria expressing same |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| EP3116303B1 (en) | 2014-01-15 | 2020-07-22 | Monsanto Technology LLC | Methods and compositions for weed control using epsps polynucleotides |
| US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
| WO2015114638A2 (en) | 2014-02-03 | 2015-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of eliminating stem cells |
| JP2017506228A (ja) | 2014-02-05 | 2017-03-02 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | セロトニン放出ホルモン、アドレナリン放出ホルモン、ノルアドレナリン放出ホルモン、グルタミン酸放出ホルモンおよび副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのマイクロrnaおよび該マイクロrnaを含む組成物 |
| US10066014B2 (en) | 2014-02-06 | 2018-09-04 | Yeda Research And Development Co. Ltd. | Anti CD84 antibodies, compositions comprising same and uses thereof |
| WO2015118547A1 (en) | 2014-02-10 | 2015-08-13 | Protalix Ltd. | Method of maintaining disease stability in a subject having gaucher's disease |
| CA2937305C (en) | 2014-02-11 | 2020-12-15 | Brainstorm Cell Therapeutics Ltd. | Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells |
| CN106255882A (zh) | 2014-03-03 | 2016-12-21 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于检测铜绿假单胞菌的方法和装置 |
| EP2923709A1 (en) | 2014-03-28 | 2015-09-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Multi-component-multistage malaria vaccine |
| EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
| CA2945438C (en) | 2014-04-10 | 2023-08-22 | Bonus Therapeutics Ltd. | Bone repair compositions |
| SI4026917T1 (sl) | 2014-04-14 | 2024-05-31 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Metoda in komplet za določanje smrti celic ali tkiva oz. izvora DNK tkiva ali celice z analizo metilacije DNK |
| WO2015159295A1 (en) | 2014-04-17 | 2015-10-22 | Yeda Research And Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
| AP2016009504A0 (en) | 2014-04-27 | 2016-10-31 | Ccam Biotherapeutics Ltd | Humanized antibodies against ceacam1 |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| ES2870658T3 (es) | 2014-04-28 | 2021-10-27 | Yeda Res & Dev | Respuesta del microbioma a agentes |
| CA2945736A1 (en) | 2014-05-04 | 2015-11-12 | Forrest Innovations Ltd. | Compositions for mosquito control and uses of same |
| US10294482B2 (en) | 2014-05-22 | 2019-05-21 | Yeda Research And Development Co. Ltd. | Recombinant microorganisms capable of carbon fixation |
| WO2015186128A1 (en) | 2014-06-02 | 2015-12-10 | Kadimastem Ltd. | Methods of inducing myelination and maturation of oligodendrocytes |
| US20170253881A1 (en) | 2014-06-02 | 2017-09-07 | Technion Research & Development Foundation Limited | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
| AU2015280252A1 (en) | 2014-06-23 | 2017-01-12 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
| EP3145951A1 (en) | 2014-06-24 | 2017-03-29 | InSight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| WO2015200539A1 (en) | 2014-06-25 | 2015-12-30 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| SG11201610630RA (en) | 2014-06-25 | 2017-01-27 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Identification of cancer stem cell markers and use of same for diagnosis and treatment |
| EP3160448B1 (en) | 2014-06-26 | 2025-08-06 | Ramot at Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
| WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
| DK3169343T3 (da) | 2014-07-15 | 2020-06-22 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Isolerede cd44-polypeptider og anvendelser heraf |
| CA2955411A1 (en) | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods for determining drug response of patient specific mutations |
| CA2955414A1 (en) | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
| WO2016018887A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| CN108064274A (zh) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
| CN111624346A (zh) | 2014-08-14 | 2020-09-04 | 米密德诊断学有限公司 | 用于预测及/或决定预后的套组 |
| WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | チロシンキナーゼ阻害薬(tki)に耐性のがんを処置するための組成物および方法 |
| EP2992895A1 (en) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
| WO2016038617A1 (en) | 2014-09-11 | 2016-03-17 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of producing mogrosides and compositions comprising same and uses thereof |
| IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
| EP3230453B1 (en) | 2014-09-21 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Downregulating mir-132 for the treatment of lipid related disorders |
| DE102015220401B4 (de) | 2014-10-20 | 2022-12-29 | Gen-Probe Incorporated | Erythrozyten-Lyselösung |
| CN107406825B (zh) | 2014-11-13 | 2022-04-08 | 恩祖迪克控股有限公司 | 甲壳纲十足目雌性动物的功能性别反转 |
| EP3220945A2 (en) | 2014-11-17 | 2017-09-27 | Yeda Research and Development Co., Ltd. | Methods of treating diseases related to mitochondrial function |
| JP2017533723A (ja) | 2014-11-17 | 2017-11-16 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | マイクロバイオーム解析方法 |
| EA038931B9 (ru) | 2014-11-20 | 2022-02-18 | Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. | Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений |
| EP3224353B9 (en) | 2014-11-26 | 2023-08-09 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Targeted elimination of bacterial genes |
| WO2016084084A1 (en) | 2014-11-27 | 2016-06-02 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
| WO2016092550A2 (en) | 2014-12-10 | 2016-06-16 | Opko Biologics Ltd. | Methods of producing long acting ctp-modified polypeptides |
| US10688330B2 (en) | 2014-12-11 | 2020-06-23 | Yeda Research And Development Co. Ltd. | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
| CA2968650A1 (en) | 2014-12-11 | 2016-06-16 | Memed Diagnostics Ltd. | Marker combinations for diagnosing infections and methods of use thereof |
| WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
| MX2017008737A (es) | 2014-12-30 | 2018-01-25 | Cell Cure Neurosciences Ltd | Poblaciones de celulas rpe y metodos para generar las mismas. |
| EP3916085A1 (en) | 2014-12-30 | 2021-12-01 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
| CA2972700A1 (en) | 2014-12-30 | 2016-07-07 | Cell Cure Neurosciences Ltd. | Methods of treating retinal diseases |
| IL253208B2 (en) | 2015-01-04 | 2023-03-01 | Protalix Ltd | Converted DNase and its uses |
| WO2016116935A1 (en) | 2015-01-21 | 2016-07-28 | Yeda Research And Development Co. Ltd. | Use of rasa2 as a prognostic and therapeutic marker for melanoma |
| PL3256589T3 (pl) | 2015-01-22 | 2022-02-21 | Monsanto Technology Llc | Kompozycje i sposoby kontrolowania leptinotarsa |
| US20180345047A1 (en) | 2015-02-26 | 2018-12-06 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
| US10781445B2 (en) | 2015-03-11 | 2020-09-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
| IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
| WO2016160618A2 (en) | 2015-03-27 | 2016-10-06 | University Of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
| KR20170132293A (ko) | 2015-03-31 | 2017-12-01 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 글루타메이트 옥살로아세테이트 트랜스아미나제 1(got1) 제제와 이의 제조방법 및 용도 |
| US10960035B2 (en) | 2015-04-01 | 2021-03-30 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) | Erodium crassifolium L'Her plant extracts and uses thereof |
| EP3280401B1 (en) | 2015-04-07 | 2021-08-25 | ELA Pharma Ltd | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto |
| EP3081575A1 (en) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
| CN108135863B (zh) | 2015-04-27 | 2021-07-27 | 特拉维夫医疗中心医学研究基础设施和保健服务基金会 | 用于治疗炎性和过度增殖性病况的egr1靶向分子 |
| CN108347945B (zh) | 2015-04-29 | 2021-03-23 | 以色列农业和农村发展部农业研究组织(范卡尼中心) | 抗植物致病组合物 |
| US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| US11845928B2 (en) | 2015-05-04 | 2023-12-19 | Tsinghua University | Methods and kits for fragmenting DNA |
| US20180161300A1 (en) | 2015-05-11 | 2018-06-14 | Yeda Research And Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
| WO2016185471A1 (en) | 2015-05-17 | 2016-11-24 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Compositions and methods for treating cancer |
| WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
| WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
| CA2986203A1 (en) | 2015-05-21 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Bacterial populations for promoting health |
| WO2016193969A2 (en) | 2015-05-29 | 2016-12-08 | Opko Biologics Ltd. | Pegylated oxyntomodulin variants |
| EP3302053B1 (en) | 2015-06-02 | 2021-03-17 | Monsanto Technology LLC | Compositions and methods for delivery of a polynucleotide into a plant |
| EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS |
| AU2016270474A1 (en) | 2015-06-04 | 2018-01-04 | University Of Southern California | Lym-1 and Lym-2 targeted CAR cell immunotherapy |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| EP3310388B1 (en) | 2015-06-18 | 2021-10-06 | Yeda Research and Development Co., Ltd. | Conditioning protocols and use of same for tissue regeneration |
| WO2016203476A1 (en) | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
| EP3988113A1 (en) | 2015-06-19 | 2022-04-27 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| AU2016291825B2 (en) | 2015-07-16 | 2022-08-11 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
| WO2017013648A1 (en) | 2015-07-19 | 2017-01-26 | Yeda Research And Development Co. Ltd. | SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE |
| CA2993023C (en) | 2015-07-22 | 2020-04-28 | Phytopharma International Ltd. | Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby |
| EP3328995B1 (en) | 2015-07-29 | 2021-03-31 | Hadasit Medical Research Services And Development | Large scale production of retinal pigment epithelial cells |
| EP3331546B1 (en) | 2015-08-03 | 2023-10-04 | Biokine Therapeutics Ltd. | Cxcr4 inhibitor for the treatment of cancer |
| WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
| EA201890442A1 (ru) | 2015-08-05 | 2018-07-31 | Селл Кьюр Нейросайансес Лтд. | Получение фоторецепторов для лечения заболеваний сетчатки |
| DK3331994T3 (da) | 2015-08-05 | 2022-11-21 | Cell Cure Neurosciences Ltd | Fremstilling af retinale pigmentepitelceller |
| WO2017025963A1 (en) | 2015-08-10 | 2017-02-16 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using cd24 |
| EP3334831A1 (en) | 2015-08-13 | 2018-06-20 | Forrest Innovations Ltd. | Formulations and compositions for delivery of nucleic acids to plant cells |
| WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
| US10765706B2 (en) | 2015-09-03 | 2020-09-08 | University Of South Florida | Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers |
| WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
| EP3365376A1 (en) | 2015-10-25 | 2018-08-29 | Yeda Research and Development Co., Ltd. | Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same |
| CA3002919A1 (en) | 2015-10-26 | 2017-05-04 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
| EP3368024B1 (en) | 2015-10-27 | 2023-09-20 | Akos Biosciences, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
| IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method of inducing cardiomyocytes proliferation and treating heart diseases |
| EP3370791A1 (en) | 2015-11-03 | 2018-09-12 | Ariel-University Research and Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
| WO2017081689A1 (en) | 2015-11-11 | 2017-05-18 | Ramot At Tel-Aviv University Ltd. | Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer |
| EP4231015B1 (en) | 2015-11-30 | 2024-10-30 | Kadimastem Ltd. | Methods for differentiating and purifying pancreatic endocrine cells |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| ES2984278T3 (es) | 2015-12-16 | 2024-10-29 | Univ Ramot | Partículas que comprenden epiplón descelularizado |
| EP3397344A4 (en) | 2015-12-28 | 2019-08-28 | B.G. Negev Technologies and Applications Ltd. at Ben-Gurion University | COMPOSITION AND METHOD FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS |
| JP2019505511A (ja) | 2016-01-06 | 2019-02-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 |
| US20190178888A1 (en) | 2016-01-11 | 2019-06-13 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
| EP3405024B1 (en) | 2016-01-21 | 2022-12-28 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Parthenocarpic plants and methods of producing same |
| IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | The composition containing sp1 protein and carbon nanoparticles and its uses |
| IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive wires |
| WO2017130205A1 (en) | 2016-01-31 | 2017-08-03 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
| CN108884137B (zh) | 2016-02-04 | 2022-04-05 | 耶达研究及发展有限公司 | 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途 |
| US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
| EP3414346B1 (en) | 2016-02-14 | 2019-11-13 | Yeda Research and Development Co. Ltd. | Microbiome-based diagnosis, prediction and treatment of relapsing obesity |
| KR20180111987A (ko) | 2016-02-16 | 2018-10-11 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 시아노박테리아 및 식물 성장 억제용 비-단백질 페닐알라닌 유사체 |
| IL260983B (en) | 2016-02-19 | 2022-07-01 | Genisphere Llc | Nucleic acid carriers and methods of medical use |
| EP3420075A4 (en) | 2016-02-23 | 2019-10-16 | Chaya Brodie | GENERATION OF CANCER STEM CELLS AND USE THEREOF |
| CN109071666B (zh) | 2016-03-01 | 2022-06-28 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 人脊髓灰质炎病毒受体(pvr)特异性抗体 |
| WO2017149547A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Analyzing rna for diagnosing infection type |
| WO2017153982A1 (en) | 2016-03-06 | 2017-09-14 | Yeda Research And Development Co. Ltd. | Method for modulating myelination |
| IL244649A0 (en) | 2016-03-17 | 2016-06-30 | Yeda Res & Dev | Methods for the isolation of barrel-like proteases and the identification of peptides that are cleaved by Alidan |
| WO2017175228A1 (en) | 2016-04-06 | 2017-10-12 | Technion Research & Development Foundation Limited | Infiltrating immune cell proportions predict anti-tnf response in colon biopsies |
| US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
| CA3232826A1 (en) | 2016-04-27 | 2017-11-02 | Gen-Probe Incorporated | Blood cell lysis reagent |
| CN109475581A (zh) | 2016-05-22 | 2019-03-15 | 耶达研究及发展有限公司 | 为了移植及诱导耐受性而使用肺细胞的方法 |
| IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
| US20190100732A1 (en) | 2016-06-02 | 2019-04-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
| EP3464322B1 (en) | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Novel molecules for the treatment of inflammation |
| WO2017212494A1 (en) | 2016-06-09 | 2017-12-14 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
| WO2017221225A1 (en) | 2016-06-19 | 2017-12-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Screening for chemotherapy resistance in human haploid cells |
| JP7334043B2 (ja) | 2016-06-27 | 2023-08-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | メモリーt細胞から作られるベト細胞 |
| WO2018011796A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| CA3027341A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| IL291373B2 (en) | 2016-07-11 | 2023-10-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Methods and systems for growing cells in culture |
| IL246722A0 (en) | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combination therapy to increase endogenous nitric oxide (no) synthesis |
| BR112019000610A2 (pt) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
| WO2018011804A1 (en) | 2016-07-11 | 2018-01-18 | Bonus Therapeutics Ltd. | Cell compositions for tissue regeneration |
| EP4434516A3 (en) | 2016-07-18 | 2025-02-26 | Ramot at Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
| US20190203270A1 (en) | 2016-07-24 | 2019-07-04 | Yeda Research And Development Co., Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
| ES2965761T3 (es) | 2016-08-08 | 2024-04-16 | Tech Innovation Momentum Fund Israel Limited Partnership | Sistemas bacterianos para el análisis de polipéptidos ubiquitilados |
| US12205677B2 (en) | 2016-08-10 | 2025-01-21 | Memed Diagnostics Ltd. | System and method for analysis of biological data |
| WO2018029693A1 (en) | 2016-08-10 | 2018-02-15 | Ramot At Tel-Aviv University Ltd. | Analysis of methylation status and copy number |
| AU2017311684B2 (en) | 2016-08-14 | 2023-05-04 | Ramot At Tel-Aviv University Ltd. | Mesenchymal cell-derived exosomes to treat neurological disorders |
| IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
| WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
| US11812746B2 (en) | 2016-08-28 | 2023-11-14 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Method of controlling fungal infections in plants |
| EP3510047A1 (en) | 2016-09-07 | 2019-07-17 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
| WO2018051347A1 (en) | 2016-09-14 | 2018-03-22 | Yeda Research And Development Co. Ltd. | Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens |
| EP3519833B1 (en) | 2016-09-29 | 2024-08-14 | MeMed Diagnostics Ltd. | Methods of prognosis and treatment |
| IL248468A0 (en) | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing |
| IL248385A0 (en) | 2016-10-18 | 2017-02-01 | Yeda Res & Dev | Treatment of circadian rhythm disorder |
| US20190359956A1 (en) | 2016-11-10 | 2019-11-28 | Yeda Research And Development Co. Ltd. | Phosphotriesterases for treating or preventing organophosphate exposure associated damage |
| WO2018096547A1 (en) | 2016-11-28 | 2018-05-31 | Yeda Research And Development Co. Ltd. | Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest |
| US20190343782A1 (en) | 2016-11-30 | 2019-11-14 | Yeda Research And Development Co. Ltd. | Methods of treating liver toxicity and disorders |
| MX2018016003A (es) | 2016-12-01 | 2019-05-16 | Univ Ramot | Tratamiento combinado para lesiones neurológicas. |
| EP3571295B1 (en) | 2017-01-18 | 2026-01-07 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
| CN110234997B (zh) | 2017-01-25 | 2023-06-16 | St创新诊断有限公司 | 诊断恶性疾病的方法 |
| IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production |
| WO2018146679A2 (en) | 2017-02-08 | 2018-08-16 | Hadasit Medical Research Services And Development Ltd. | Photoreceptor cells for the treatment of retinal diseases |
| IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
| US20200150125A1 (en) | 2017-03-12 | 2020-05-14 | Yeda Research And Development Co., Ltd. | Methods of diagnosing and prognosing cancer |
| WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| KR20200031559A (ko) | 2017-03-16 | 2020-03-24 | 리니지 셀 테라퓨틱스, 인크. | 망막 질환 요법의 치료 효과를 측정하는 방법 |
| SI3607050T1 (sl) | 2017-04-05 | 2024-02-29 | Yeda Research And Development Co. Ltd. | Ex-vivo kulturni sistem in postopki uporabe le-tega |
| IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
| WO2018207184A2 (en) | 2017-05-10 | 2018-11-15 | Ariel Scientific Innovations Ltd. | Methods of purifying antibodies |
| WO2018216006A1 (en) | 2017-05-21 | 2018-11-29 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Combination of markers for diagnosing cancer |
| WO2018216011A1 (en) | 2017-05-23 | 2018-11-29 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
| WO2018220582A1 (en) | 2017-05-31 | 2018-12-06 | Tropic Biosciences UK Limited | Methods of selecting cells comprising genome editing events |
| GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
| GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
| WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
| EP3652344A1 (en) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Dna targets as tissue-specific methylation markers |
| EP3652342A1 (en) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Detecting tissue-specific dna |
| US11466323B2 (en) | 2017-07-13 | 2022-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules |
| IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
| EP3665283A4 (en) | 2017-08-08 | 2021-04-21 | Technology Innovation Momentum Fund (Israel) Limited Partnership | CHLORAMPHENICOL RESISTANT SPLIT PROTEIN AND USES THEREOF |
| IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
| CA3073254A1 (en) | 2017-08-21 | 2019-02-28 | Ramot At Tel Aviv University Ltd. | Methods of diagnosing and treating lung cancer |
| US11692166B2 (en) | 2017-08-23 | 2023-07-04 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
| WO2019058253A1 (en) | 2017-09-19 | 2019-03-28 | Tropic Biosciences UK Limited | MODIFICATION OF THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENE EXPRESSION IN EUKARYOTIC CELLS |
| EA202090585A1 (ru) | 2017-09-19 | 2020-07-08 | Дзе Стэйт Оф Исраэль, Министри Оф Эгрикалчур Энд Рурал Девелопмент, Эгрикалчурал Ресерч Организэйшн (Аро) (Волкани Сентер) | Птицы с отредактированным геномом |
| CN111565731B (zh) | 2017-10-24 | 2024-03-08 | 达莉亚·伊兰妮 | 治疗缺血性疾病的方法 |
| EP3706795A4 (en) | 2017-11-09 | 2021-10-13 | Pinteon Therapeutics Inc. | METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES |
| IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
| EP3717032B1 (en) | 2017-11-29 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Methods of preventing or treating neurogenic shock |
| AR114936A1 (es) | 2017-11-29 | 2020-11-11 | Weedout Ltd | Composiciones, kits y métodos para controlar la maleza del género amaranthus |
| WO2019106680A1 (en) | 2017-12-03 | 2019-06-06 | Yeda Research And Development Co. Ltd. | Treatment of an ischemic heart disease |
| WO2019116376A1 (en) | 2017-12-17 | 2019-06-20 | Yeda Research And Development Co. Ltd. | Cop9 signalosome (csn) complex modulators and uses thereof |
| WO2019130313A1 (en) | 2017-12-28 | 2019-07-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method to reproduce circadian rhythms on a microfluidic chip |
| EP4610372A3 (en) | 2018-01-29 | 2025-10-29 | Lavie Bio Ltd. | Plant microbial preparations, compositions and formulations comprising same and uses thereof |
| IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| IL257269A (en) | 2018-01-31 | 2018-04-09 | Olender Tsviya | Signaling is directed to the endoplasmic reticulum |
| WO2019155459A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Inhibitors of the 20s proteasome |
| EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
| WO2019162945A1 (en) | 2018-02-23 | 2019-08-29 | Carmel Haifa University Economic Corporation Ltd. | Methods for treating memory impairment and cognitive dysfunction |
| WO2019167047A1 (en) | 2018-02-28 | 2019-09-06 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of diagnosing and treating bladder cancer |
| EP3765034A1 (en) | 2018-03-12 | 2021-01-20 | Yeda Research and Development Co. Ltd | Treatment of a heart disease |
| CA3093838A1 (en) | 2018-03-14 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Anti-polysialic acid antibodies and uses thereof |
| WO2019186569A1 (en) | 2018-03-29 | 2019-10-03 | Yeda Research And Development Co. Ltd. | Use of electric field gradients to control gene expression |
| IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
| US11648260B2 (en) | 2018-03-29 | 2023-05-16 | Technion Research And Development Foundation Limitted | Vesicles comprising a PTEN inhibitor and uses of same |
| GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
| WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
| IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neoantigens |
| JP2021525233A (ja) | 2018-05-27 | 2021-09-24 | バイオラインアールエックス・リミテッドBioLineRx Ltd. | 固形腫瘍を治療するためにチェックポイント阻害剤と併用するagi−134 |
| IL279108B2 (en) | 2018-05-31 | 2024-10-01 | Immunity Pharma Ltd | Compositions and methods of using same for treating amyotrophic lateral sclerosis (als) |
| WO2019234750A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of regenerating and transforming cannabis |
| EP3802839A1 (en) | 2018-06-07 | 2021-04-14 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Nucleic acid constructs and methods of using same |
| WO2020003311A1 (en) | 2018-06-25 | 2020-01-02 | Yeda Research And Development Co. Ltd. | Systems and methods for increasing efficiency of genome editing |
| EP3818075A1 (en) | 2018-07-04 | 2021-05-12 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
| WO2020012467A2 (en) | 2018-07-08 | 2020-01-16 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
| KR20210044220A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| EA202190249A1 (ru) | 2018-07-11 | 2021-05-21 | Иммунити Фарма Лтд. | Пептидные соединения и их терапевтическое применение |
| KR20210042430A (ko) | 2018-07-31 | 2021-04-19 | 콜플랜트 리미티드 | 담배 형질전환 이벤트 및 이의 검출 방법 및 용도 |
| IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
| CN113227359A (zh) | 2018-08-24 | 2021-08-06 | 耶达研究及发展有限公司 | 调节m2巨噬细胞极化的方法及其在治疗中的用途 |
| US20210353611A1 (en) | 2018-09-20 | 2021-11-18 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral sclerosis |
| EP3856225A1 (en) | 2018-09-25 | 2021-08-04 | BioLineRx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
| IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| US12478571B2 (en) | 2018-12-17 | 2025-11-25 | Pontis Biologics, Inc. | Enzyme based compositions and methods for removing dental calculi |
| WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
| WO2020159445A1 (en) | 2019-01-31 | 2020-08-06 | Agency For Science, Technology And Research | Cnx/erp57 inhibitor for use in the treatment or prevention of cancer |
| IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof |
| IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| EP3927807A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods of generating organoids for high throughput screening of drugs |
| EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
| US12565664B2 (en) | 2019-03-05 | 2026-03-03 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Genome-edited birds |
| EP3938400B1 (en) | 2019-03-11 | 2025-07-30 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
| GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
| GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
| IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| WO2020202142A2 (en) | 2019-03-31 | 2020-10-08 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| IL266433B (en) | 2019-05-02 | 2020-11-30 | Sagi Irit | Preparations containing the propeptide of lysyl oxidase and their uses |
| US20220220559A1 (en) | 2019-05-13 | 2022-07-14 | Yeda Research And Development Co. Ltd. | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases |
| IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| AU2020279080B2 (en) | 2019-05-22 | 2025-11-27 | Hadasit Medical Research Services And Development Ltd. | Methods of culturing human pluripotent cells |
| GB2598520B (en) | 2019-05-28 | 2024-07-24 | Univ Shanghai Technology | Composition and methods to treat ectodermal dysplasia 2, Clouston type |
| JP7668233B2 (ja) | 2019-06-12 | 2025-04-24 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | オリゴデンドロサイトの産生方法 |
| WO2020255124A1 (en) | 2019-06-16 | 2020-12-24 | Yeda Research And Development Co. Ltd. | Method for stabilizing intracellular rna |
| EP3990488A4 (en) | 2019-06-27 | 2023-09-13 | Ramot at Tel-Aviv University Ltd. | SEMAPHORIN-3A ANTIBODIES AND USES THEREOF |
| CA3145972A1 (en) | 2019-07-04 | 2021-01-07 | Ukko Inc. | De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity |
| CA3146248A1 (en) | 2019-07-11 | 2021-01-14 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
| WO2021009740A1 (en) | 2019-07-16 | 2021-01-21 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
| IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
| EP4004548B1 (en) | 2019-07-29 | 2026-01-14 | Yeda Research and Development Co. Ltd | Methods of treating and diagnosing lung cancer |
| WO2021019536A1 (en) | 2019-07-30 | 2021-02-04 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
| WO2021028909A1 (en) | 2019-08-12 | 2021-02-18 | Yeda Research And Development Co. Ltd. | Dna repair blood test for predicting response of lung cancer patients to immunotherapy |
| US20240140988A1 (en) | 2019-08-22 | 2024-05-02 | Ariel Scientific Innovations Ltd. | Scaled-up methods for purifying antibodies |
| EP4021463A1 (en) | 2019-08-27 | 2022-07-06 | Yeda Research and Development Co. Ltd | Treatment of bacterial vaginosis |
| WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
| IL269674B (en) | 2019-09-25 | 2020-08-31 | Roy Bar Ziv | Assembling protein complexes on a chip |
| JP7754506B2 (ja) | 2019-10-08 | 2025-10-15 | ネクチン セラピューティクス エルティーディー. | ポリオウイルス受容体(pvr)に対する抗体およびその使用 |
| IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
| EP4051695A1 (en) | 2019-10-31 | 2022-09-07 | Yeda Research and Development Co., Ltd. | Engineered autotrophic bacteria for co2 conversion to organic materials |
| BR112022009087A2 (pt) | 2019-11-11 | 2022-07-26 | Ibi Ag Innovative Bio Insecticides Ltd | Nanocorpos para controle de insetos e usos dos mesmos |
| JP7558272B2 (ja) | 2019-11-19 | 2024-09-30 | プロタリクス リミテッド | 形質転換細胞からの構築物の除去 |
| IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
| EP4077731A1 (en) | 2019-12-22 | 2022-10-26 | Yeda Research and Development Co. Ltd | Diagnosis of frontotemporal dementia |
| IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
| WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
| IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods for treating atopic dermatitis |
| IL272074B2 (en) | 2020-01-15 | 2024-12-01 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
| IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
| BR112022014490A2 (pt) | 2020-01-22 | 2022-10-11 | Univ Ramot | Anticorpos anti-ide e seus usos |
| WO2021152584A1 (en) | 2020-01-28 | 2021-08-05 | Ariel Scientific Innovations Ltd. | Methods of analyzing cell membranes |
| EP4097485A4 (en) | 2020-01-29 | 2024-05-15 | MeMed Diagnostics Ltd. | METHODS OF DIAGNOSIS AND CLASSIFICATION OF VIRAL INFECTIONS |
| EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
| WO2021152586A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
| IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
| IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
| JP2023513334A (ja) | 2020-02-09 | 2023-03-30 | エヌエルシー ファーマ リミテッド | Sars-cov-2の迅速検出検査 |
| IL272586A (en) | 2020-02-10 | 2021-08-31 | Yeda Res & Dev | A method for cell cluster analysis |
| WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
| WO2021186431A1 (en) | 2020-03-16 | 2021-09-23 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein |
| AU2021245409A1 (en) | 2020-03-29 | 2022-11-24 | Yeda Research And Development Co. Ltd. | Variants of beta-glucocerebrosidase for use in treating Gaucher Disease |
| AU2021248783A1 (en) | 2020-03-31 | 2022-12-01 | Biomuse Ltd. | Bacteria for the prevention and treatment of smoke-induced lung damage |
| WO2021205444A1 (en) | 2020-04-06 | 2021-10-14 | Yeda Research And Development Co. Ltd. | Methods of diagnosing cancer and predicting responsiveness to therapy |
| WO2021205459A1 (en) | 2020-04-07 | 2021-10-14 | Ramot At Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
| IL297228A (en) | 2020-04-13 | 2022-12-01 | Exoprother Medical Ltd | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
| US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| WO2021229577A1 (en) | 2020-05-12 | 2021-11-18 | Collplant Ltd. | Collagen as a delivery tool for metal-based anti-viral agents |
| IL274811B (en) | 2020-05-20 | 2021-05-31 | Yeda Res & Dev | Spatial information is developed for the analysis of individual cells |
| EP4521115A3 (en) | 2020-06-10 | 2025-06-11 | Ramot at Tel-Aviv University Ltd. | Methods of detecting methylated cpg |
| EP4168438A4 (en) | 2020-06-22 | 2024-07-10 | Ramot at Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
| WO2022038539A2 (en) | 2020-08-18 | 2022-02-24 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| US20230309480A1 (en) | 2020-08-18 | 2023-10-05 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
| IL277488A (en) | 2020-09-21 | 2022-04-01 | Yeda Res & Dev | Weight regulation method |
| EP4217370A2 (en) | 2020-09-23 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods and compositions for treating coronaviral infections |
| IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
| EP4225902A1 (en) | 2020-10-05 | 2023-08-16 | Protalix Ltd. | Dicer-like knock-out plant cells |
| IL301970A (en) | 2020-10-07 | 2023-06-01 | Protalix Ltd | Long-acting dnase |
| WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
| IL278401A (en) | 2020-10-29 | 2022-05-01 | Yeda Res & Dev | Polynucleotides for editing RNA and a method for using them |
| EP4240856A2 (en) | 2020-11-09 | 2023-09-13 | 1E Therapeutics, Ltd. | Catalytic sequence based methods of treating or preventing bacterial infections |
| AU2021387979A1 (en) | 2020-11-26 | 2023-03-30 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
| IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling ubiquitination of mlkl for treatment of disease |
| AU2021416356B2 (en) | 2020-12-28 | 2026-02-26 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| WO2022144882A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| WO2022149142A2 (en) | 2021-01-10 | 2022-07-14 | Supermeat The Essence Of Meat Ltd. | Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry |
| US20240083843A1 (en) | 2021-01-14 | 2024-03-14 | Yeda Research And Development Co. Ltd. | Methods of producing vitamin d |
| IL280340B (en) | 2021-01-21 | 2022-04-01 | Yeda Res & Dev | Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection |
| IL305314A (en) | 2021-02-18 | 2023-10-01 | Yeda res & development co ltd | Genetically modified bacteria for generating vaccines |
| JP2024506955A (ja) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ワクチンを作製する方法 |
| IL281561A (en) | 2021-03-16 | 2022-10-01 | Yeda Res & Dev | Methods and devices for ex-utero mouse embryonic development |
| WO2022208369A1 (en) | 2021-03-30 | 2022-10-06 | Biomx Ltd. | Pseudomonas bacteriophage and uses thereof |
| IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | Combined use of ketamine and bretigabine for the treatment of psychiatric disorders |
| US20240415904A1 (en) | 2021-05-12 | 2024-12-19 | Biomx Ltd. | Staphylococcus bacteriophage and uses thereof |
| IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases |
| WO2022259242A1 (en) | 2021-06-06 | 2022-12-15 | Yeda Research And Development Co. Ltd. | Combined treatment for cancer |
| CN117836402A (zh) | 2021-06-13 | 2024-04-05 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 重编程人细胞的方法 |
| MX2023015233A (es) | 2021-06-16 | 2024-01-31 | Seedx Tech Inc | Metodos de clasificacion de semillas de matthiola. |
| NL2028466B1 (en) | 2021-06-16 | 2022-12-21 | Sakata Holland B V | Methods of sorting matthiola seeds |
| US20240287535A1 (en) | 2021-07-02 | 2024-08-29 | Tropic Biosciences UK Limited | Delay or prevention of browning in banana fruit |
| WO2023286059A1 (en) | 2021-07-13 | 2023-01-19 | Technion Research & Development Foundation Limited | Compositions and methods for treating a medical condition |
| KR20240046506A (ko) | 2021-07-18 | 2024-04-09 | 가미다-셀 리미티드 | 치료용 nk세포 집단 |
| WO2023002492A1 (en) | 2021-07-22 | 2023-01-26 | Yeda Research And Development Co. Ltd. | Codon optimization of nucleic acids |
| WO2023012584A2 (en) | 2021-08-03 | 2023-02-09 | Genicity Limited | Engineered tcr complex and methods of using same |
| EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
| WO2023018621A1 (en) | 2021-08-10 | 2023-02-16 | Gamida-Cell Ltd. | Engineered nk cells, methods of their production and uses thereof |
| GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
| GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| EP4444864A1 (en) | 2021-12-08 | 2024-10-16 | Yeda Research and Development Co. Ltd | Multipotent lung progenitor cells for lung regeneration |
| WO2023209708A1 (en) | 2022-04-25 | 2023-11-02 | Yeda Research And Development Co. Ltd. | Compositions for altering cyclic adp-ribose secondary messenger signalling |
| WO2025150045A1 (en) | 2024-01-12 | 2025-07-17 | Gabriel Nussbaum | Bacterial targets, therapeutics, compositions, kits and methods of use in treating and/or preventing cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| US3652761A (en) * | 1969-09-04 | 1972-03-28 | Corning Glass Works | Immunochemical composites and antigen or antibody purification therewith |
-
1970
- 1970-12-28 NL NL707018838A patent/NL154599B/xx not_active IP Right Cessation
-
1971
- 1971-12-10 US US00206952A patent/US3839153A/en not_active Expired - Lifetime
- 1971-12-13 ZA ZA718332A patent/ZA718332B/xx unknown
- 1971-12-13 CA CA129,950A patent/CA964560A/en not_active Expired
- 1971-12-15 IL IL38371A patent/IL38371A/xx unknown
- 1971-12-16 AU AU36986/71A patent/AU467394B2/en not_active Expired
- 1971-12-17 GB GB5873871A patent/GB1348938A/en not_active Expired
- 1971-12-22 FR FR7146179A patent/FR2120835A5/fr not_active Expired
- 1971-12-23 FI FI3669/71A patent/FI54034C/fi active
- 1971-12-23 AT AT1108971A patent/AT320145B/de not_active IP Right Cessation
- 1971-12-23 BR BR8553/71A patent/BR7108553D0/pt unknown
- 1971-12-23 SE SE7116552A patent/SE398557B/xx unknown
- 1971-12-23 IT IT54975/71A patent/IT965020B/it active
- 1971-12-24 CH CH1892971A patent/CH557030A/xx not_active IP Right Cessation
- 1971-12-26 EG EG552/71A patent/EG11604A/xx active
- 1971-12-27 ES ES398372A patent/ES398372A1/es not_active Expired
- 1971-12-27 JP JP724140A patent/JPS5834783B1/ja active Granted
- 1971-12-27 DE DE19712164768 patent/DE2164768B2/de not_active Ceased
- 1971-12-27 BE BE777309A patent/BE777309A/nl not_active IP Right Cessation
- 1971-12-28 DK DK639871A patent/DK150690C/da active
-
1982
- 1982-11-02 JP JP57193266A patent/JPS58117456A/ja active Pending
- 1982-11-02 JP JP57193265A patent/JPS58117455A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NL154599B (nl) | 1977-09-15 |
| DE2164768B2 (de) | 1976-01-22 |
| FR2120835A5 (da) | 1972-08-18 |
| FI54034C (fi) | 1978-09-11 |
| JPS58117456A (ja) | 1983-07-13 |
| CH557030A (de) | 1974-12-13 |
| AT320145B (de) | 1975-01-27 |
| AU467394B2 (en) | 1975-11-27 |
| GB1348938A (en) | 1974-03-27 |
| IL38371A (en) | 1974-06-30 |
| BR7108553D0 (pt) | 1973-07-03 |
| IL38371A0 (en) | 1972-02-29 |
| ZA718332B (en) | 1972-09-27 |
| CA964560A (en) | 1975-03-18 |
| SE398557B (sv) | 1977-12-27 |
| EG11604A (en) | 1977-08-15 |
| IT965020B (it) | 1974-01-31 |
| BE777309A (nl) | 1972-04-17 |
| FI54034B (fi) | 1978-05-31 |
| DE2164768A1 (de) | 1972-07-20 |
| DK150690C (da) | 1988-06-06 |
| US3839153A (en) | 1974-10-01 |
| AU3698671A (en) | 1973-06-21 |
| NL7018838A (da) | 1972-06-30 |
| JPS5834783B1 (da) | 1983-07-28 |
| JPS58117455A (ja) | 1983-07-13 |
| ES398372A1 (es) | 1975-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK150690B (da) | Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse | |
| USRE31006E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
| Guesdon et al. | The use of avidin-biotin interaction in immunoenzymatic techniques. | |
| US4828985A (en) | Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods | |
| US3791932A (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
| US4235960A (en) | Competitive enzyme-linked immunoassay | |
| USRE29169E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
| US4232001A (en) | Methods and materials for detection of estrophilin | |
| US4427781A (en) | Particle agglutination immunoassay with agglutinator for determining haptens; PACIA | |
| US4477576A (en) | Antigen assay method and kit | |
| US4621048A (en) | Reagents containing an anti-ligand bound to an anti-enzyme and methods for employing said reagents in an immunoassy | |
| HOSODA et al. | Effect of bridge heterologous combination on sensitivity in enzyme immunoassay for cortisol | |
| EP0383313A2 (en) | Reagent for immunoassay, and kit containing the same | |
| US4693969A (en) | Reagent for use in a sandwich solid-phase enzyme-immunoassay and process for employing same | |
| EP0124366A2 (en) | Method of measuring biological ligands | |
| Mariotti et al. | A new solid phase immunoradiometric assay for antithyroid microsomal antibody | |
| US6555388B1 (en) | Binding protein capture assay | |
| US9891214B2 (en) | Immunological assay method | |
| JPH081436B2 (ja) | 生物学的液体中の遊離リガンドの測定方法および測定用キット | |
| JPH0731191B2 (ja) | チログロブリンを使用する甲状腺ホルモンの免疫定量法 | |
| EP0338045B1 (en) | Solid-phase non-separation enzyme assay | |
| Abdul-Ahad et al. | An enzyme-linked immunosorbent assay (ELISA) for bovine LH capable of monitoring fluctuations in baseline concentrations | |
| Pratt et al. | Specificity of immunoassays: II. Heterogeneity of specificity of antibodies in antisera used for steroid immunoassay and the selective blocking of less specific antibodies, including a new method for the measurement of immunoassay specificity | |
| EP0100395B1 (en) | Reagent for determination of human urine kallikrein | |
| JPS63111467A (ja) | 免疫測定方法 |